書籍詳細

序章

P.5 掲載の参考文献

• 1) 日本透析医学会統計調査委員会:我が国の慢性透析療法の現況, 2004 (http://www.jsdt.or.jp/index.html)

• 2) Kobayashi Y, Hiki Y, Kokubo T, et al:Steroid therapy during the early stage of progressive Ig nephropathy. A 10-year follow-up study. Nephron 72:237-242, 1996

• 3) Pozzi C, Andrulli S, Del Vecchio L:Corticosteroid effectiveness in IgA nephropathy:Long-term result of a randomized, controlled trial. J Am Soc Nephrol 15:157-163, 2004
  pubmed

• 4) Hotta O, Miyazaki M, Furuta T, et al:Tonsillectomy and steroid pulse therapy significantly impact in patients with IgA nephropathy. S Am J Kidney Dis 38:736-742, 2001

• 5) Xie Y, Nishi S, Ueno M, et al:The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 65:1861-1867, 2003

• 6) Praga M, Gutierrez E, Gonzalez E, et al:Treatment of IgA nephropathy with ACE inhibitors:a randomized and controlled trial. J Am Soc Nephrol 14:1578-1583, 2003

• 7) 堺 秀人ほか:急速進行性腎炎症候群の診療指針.日腎誌 44:55-82, 2002

• 8) de Groot K, Adu D, Savage C:The value of pulse cyclophosphamide in ANCA-associated vasculitis:metanalysis and critical review. Nephrol Dial Transplant 16:2018-2027, 2001

• 9) Jayne D, Rasmussen N, Andrassy K, et al:A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36-44, 2003
  pubmed

• 10) 武曾恵理:MPO-ANCA関連腎炎血管炎への経静脈敵ガンマグロブリン療法の展望.医学のあゆみ 266:157-159, 2003

• 11) Mok C, Lai K:Mycophenolate mofetil in lupus glomeru-lonephritis. Am J Kid Dis 40:447-457, 2002

• 12) Contreras G, Pardo V, Leclercq B, et al:Sequential therapies for proliferative lupus nephritis. Engl J Med 350:971-980, 2004

• 13) Maes B, Oyen R, Claes K, et al:Mycophenolate mofetil in IgA nephropathy:results of a 3-year prospective placebo-controlled randomized study. Kidney Int 65:1842-1849, 2004
  pubmed

• 14) Yuzawa K, Konishi A, Takehana K, et al:APC0576:a novel small molecule, immunosuppressive agent effective in primate models. Transplantation 75:1463-1468, 2003
  pubmed

• 15) Ishii M, Suzuki Y, Takeshita K, et al:Inhibition of c-Jun NH2-terminal kinase activity improves ischemia/reperfusion inj ury in rat lungs. J Immunol 172:2569-2577, 2004

• 16) Tedesco-Silva HMG, Kahan BD, Boira JG, et al:FTY720, a novel immunomodulator:efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 77:1826-1833, 2004

• 17) National-Kidney-Foundation. Am J Kid Dis 39 (2) (Suppl 1):2002

• 18) Kubo M, et al:Effect of hyperinsulinemia on renal function in a general Japanese population:The Hisayama study. Kidney Int 55:2540, 1999

• 19) Iseki K, Ikeyama Y, Iseki C, et al:Proteinuria and the risk of developing end-stage renal diseases. Kidney Int 63:1268, 2003

• 20) Peterson J, Adler S, Burkart J, et al:Blood pressure control, proteinuria, and the progression ofrenal disease. Ann Intern Med 123:754, 1995

• 21) Torres v, wang x, Qian Q, et al:Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10:363-364, 2004

• 22) Shoji TY, Fujii M, Imai E:Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 66:1212-1220, 2004

• 23) Davies S, Woodrow G, Donovan K, et al:Icodextrin improves the fluid status of peritoneal dialysis patients:results of a double-blind randomized controlled trial. J Am Soc Nephrol 14:2338-2344, 2003
  pubmed

• 24) Park W, Grande J, Ninova D, et al:Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant:952-960, 2003
  pubmed

• 25) Takahashi K:Accommodation in ABO-incompatible kidney transplantation:why do kidney grafts survive?Transplant Proc 36 (2) (Suppl):S193-196, 2004

第1章 腎臓病の分子生物学

P.12 掲載の参考文献

• 1) Prashar Y, Weissman SM:READS:A methods for display of 3'-end fragments of restriction enzyme-digested cDNAs for analysis of differential gene expression. Methods Enzymol 303:258-272, 1999
  pubmed

• 2) Waga I, Yamamoto J, Sasai H, et al:Altered mRNA expression in renal biopsy tissue from patients with IgA nephropathy. Kidney Int 64:1253-1264, 2003
  pubmed

• 3) Higuchi T, Orita T, Nakanishi S, et al:Molecular cloning, genomic structure, and expression analysis of MUC20, a novel mucin protein, up-regulated in injured kidney. J Biol Chem 279:1968-1979, 2004

• 4) Higuchi T, Orita T, Katsuya K, et al:MUC20 suppresses HGF-induced Grb2-Ras pathway by binding to a multi-functional docking site of Met. Mol Cell Biol 24:7456-7468, 2004

• 5) Hollingsworth R, White JH:Target discovery using the yeast two-hybrid system. Drug Discovery Today:TARGETS 3:97-103, 2004

• 6) Nagaike M, Hirano S, Tajima H, et al:Renotropic functions of hepatocyte growth factor in renal regeneration after unilateral nephrectomy. J Biol Chem 266:22781-22784, 1991

P.18 掲載の参考文献

• 1) Ruggenenti P, Perna A, Mosconi L, et al:Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo ltaliano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 53:1209-1216, 1998

• 2) Nakajima H, Takenaka M, Kaimori JY, et al:Gene expression profile of renal proximal tubules regulated by proteinuria. Kidney Int 61:1577-1587, 2002
  pubmed

• 3) Takenaka M, Imai E, Kaneko T, et al:Isolation of genes identified in mouse renal proximal tubul by comparing different gene expression profiles. Kidney Int 53:562-572, 1998

• 4) Kaimori JY, Takenaka M, Nakajima H, et al:Induction of glia maturation factor-beta in proximal tubular cells leads to vulnerability to oxidative injury through the p38 pathway and challges in antioxidant enzyme activities. J Biol Chem 278:33519-33527, 2003
  pubmed

• 5) Nakajima H, Takenaka M, Kaimori JY, et al:Activation of the signal transducer and activator of transcription signaling pathway in renal proximal tubular cells by albumin. J Am Soc Nephrol 15:276-285, 2004
  pubmed

• 6) Takaya K, Koya D, Isono M, et al:Involvement of ERK pathway in albumin-induced MCP-1 expression in mouse proximal tubular cells. Am J Physiol Renal Physiol 284:F1037-1045, 2003
  pubmed

• 7) Kamjjo A, Kimura K, Sugaya T, et al:Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int 62:1628-1637, 2002
  pubmed

P.22 掲載の参考文献

• 1) Ross R:The pathogenesis of atherosclerosis-an update. New Engl J Med 314:488-500, 1986
  pubmed

• 2) Iwaki K, Tsujioka K, Kajiya F, et al:Decrease in the amount of focal adhesion kinase (p125 <FAK>)in interleukin-1beta-stimulated human umbilical vein endothelial cells by binding ofhuman monocytic cell lines. J Biol Chem 272 (33):20665-20670, 1997

• 3) Giaever I, Keese R:Amorphological biosensor for mammalian cells. Nature 366:591-592, 1993

• 4) Binnig G, Rohrer DH:Scanning tunneling microscopy. Surface Science 126:236-244, 1983

• 5) Binnig G, Quate CF, Gerber C:Atomic force microscope. Phys Rev Lett 56 (9):930-933, 1986
  pubmed

• 6) Sato M, Nagayama K, Kataoka N, et al:Local mechanical properties measured by atomic force microscopy for cultured bovine endothelial cells exposed to shear stress. J Biomech 33:127-135, 2000
  pubmed

• 7) Kataoka N, Hashimoto K, Kajiya F, et al:Measurements of endothelial cell-to-cell and cell-to-substrate gaps and micromechanical properties of endothelial cells during monocyte adhesion. Proc Natl Acad Sci USA 99 (24):15638-15643, 2002
  pubmed

• 8) Moy AB, Winter M, Kamath A, et al:Histamine alters endothelial barrier function at cell-cell and cell-matrix sites. Am J Physiol 278 (5):L888-898, 2000

• 9) Noiri E, Lee E, Testa J, et al:Podokinesis in endothelial cell migration:role of nitric oxide. Am J Physiol 274 (1):C236-244, 1998
  pubmed

• 10) DePaola N, Phelps JE, Florez L, et al:Electrical impedance of cultured endothelium under fluid flow. Ann Biomed Eng 29 (8):648-656, 2001
  pubmed

• 11) Hansma HG, Vesenka J, Siegerist C, et al:Reproducible imaging and dissection of plasmid DNA under liquid with the atomic force microscope. Science 256 (5060):1180-1184, 1992
  pubmed

• 12) Barbee KA, Davies PF, Lal R:Shear stress-induced reorganization of the surface topography of livin endotheial cells imaged by atomic force microscopy. Circ Res 74 (1):163-171, 1994

• 13) Hashimoto K, Kataoka N, F Kajiya, et al:Direct observation and quantitative analysis of spatiotemporal dynamics of individual living monocytes during transendothelial migration. Atherosclerosis 177 1):19-27, 2004

P.27 掲載の参考文献

• 1) Jeunemaitre X:Genetics of diabetic complications:nephropathy. Ann Endocrinol (Paris) 65:S10-16, 2004
  pubmed

• 2) Solini A, Dalla Vestra M, Saller A, et al:The angiotensin-converting enzyme DD genotype is associated with glomerulopathy lesions in type 2 diabetes. Diabetes 51:251-255, 2002
  pubmed

• 3) Gharavi AG, Yan Y, Scolari F, et al:IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 26:354-357, 2000
  pubmed

• 4) Schena FP, Cerullo G, Rossini M, et al:Increased risk of end-stage renal disease in familial IgA nephropathy. J Am Soc Nephrol 13:453-460, 2002
  pubmed

• 5) Takei T, Iida A, Nitta K, et al:Association between single-nucleotide polymorphisms in selectin genes and immunoglobulin A nephropathy. Am J Hum Genet 70:781-786, 2002
  pubmed

• 6) Akiyama F, Tanaka T, Yamada R, et al:Single-nucleotide polymorphisms in the class II region ofthe major histocompatibility complex in Japanese patients with immunoglobulin A nephropathy. J Hum Genet 47:532-538, 2002

• 7) Hiki Y, Odani H, Takahashi M, et al:Mass spectrometry proves under-0-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 59:1077-1085, 2001

• 8) Narita I, Saito N, Goto S, et al:Role of uteroglobin G38A polymorphism in the progression of IgA nephropathy in Japanese patients. Kidney Int 31:1853-1858, 2002

• 9) Li YJ, Du Y, Li CX, et al:Family-based association study showing that immunoglobulin A nephropathy is associated with the polymorphisms 2093C and 2180T in the 3:untranslated region ofthe Megsin gene. J Am Soc Nephrol 15:1739-1743, 2004

• 10) Frimat L, Philippe C, Maghakian MN, et al:Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and endstage renal failure in IgA nephropathy:IGARAS-a study of 274 Men. J Am Soc Nephrol 11:2062-2067, 2000

• 11) Goto S, Narita I, Saito N, et al:A (-20) Cpolymorphism of the angiotensinogen gene and progression of IgA nephropathy. Kidney Int 62:980-985, 2002

• 12) Narita I, Goto S, Saito N, et al:Angiotensinogen gene variation and renoprotective efficacy ofrenin-angiotensin system blockade in IgA nephropathy. Kidney lnt 64:1050-1058, 2003

• 13) Narita I, Goto S, Saito N, et al:Renoprotective efficacy of renin-angiotensin inhibitors in IgA nephropathy is influenced by ACE A2350G polymorphism. J Med Genet 40:E130, 2003
  pubmed

• 14) Song J, Narita I, Goto S, et al:Gender Specific Association of Aldosterone Synthase Gene Polymorphism with Renal Survival in Patients with IgA Nephropathy. J Med Genet 40:372-376, 2003
  pubmed

• 15) Narita I, Goto S, Saito N, et al:Interaction Between ACE and ADD1 Gene Polymorphisms in the Progression of IgA Nephropathy in Japanese Patients. Hypertension 42:304-309, 2003
  pubmed

P.32 掲載の参考文献

• 1) Brown EM, Gamba G, Riccardi D, et al:Cloning and char-acterization of an extracellular Ca?+-sensing receptor from bovine parathyroid. Nature 366:575-580, 1993

• 2) Pollak MR, Brown EM, Chou YH, et al:Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyper-parathyroidism. Cell 75:1297-1303, 1993

• 3) Ho C, Conner DA, Pollak MR, et al:A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet 11:389-394, 1995
  pubmed

• 4) Pollak MR, Brown EM, Estep HL, et al:Autosomal dominant hypocalcemia caused by a Ca2+-sensing receptor gene mutation. Nat Genet 8:303-307, 1994
  pubmed

• 5) Pearce SH, Williamson C, Kifor O, et al:A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 335:1115-1122, 1996
  pubmed

• 6) Hebert SC:Bartter syndrome. Curr Opin Nephrol Hypertens 12:527-532, 2003
  pubmed

• 7) Wang W-H, Lu M, Hebert SC:Cytochrome P-450 metabolites mediate extracellular Ca2+-induced inhibition of api-cal K+channels in the TAL. Am J Physiol 271:C103-111, 1996

• 8) Wang W,Lu M, Balazy M, et al:Phospholipase A2 is involved in mediating the effect of extracellular Ca?+on apical K+channels in rat TAI.. Am J Physiol 273:F421-429, 1997

• 9) Watanabe S, Fukumoto S, Chang H, et al:Association between activating mutations of calcium-sensing recep-tor and Bartter:s syndrome. Lancet 360:692-694, 2002

• 10) Vargas-Poussou R, Huang C, Hulin P, et al:Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol 13:2259-2266, 2002
  pubmed

P.36 掲載の参考文献

• 1) Bazzoni G, Dejana E:Endothelial cell-to-cell junctions:molecular organization and role in vascular homeostasis. Physiol Rew 84:869-901, 2004

• 2) Schneeberger EE, Lynch RD:The tight junction:a multifunctional complex. Am J Physiol Cell Physiol 286:C1213-1228, 2004
  pubmed

• 3) Sawada N, et al:Tight junctions and human diseases. Med Electron Microsc 36:147-156, 2003
  pubmed

• 4) Wilson FH, et al:Molecular pathogenesis of inherited hypertension with hyperkalemia:The Na-CI cotransporter is inhibited by wild-type but not mutant WNK4. PNAS 100:680-684, 2003

• 5) Yang CL, et al:WNK kinases regulate thiazide-sensitive Na-CI cotransport. J Clin Invest 111:1039-1045, 2003

• 6) Yamauchi K, et al:Disease-causing mutant WNK4 increases paracellular chloride permeability and phosphorylates claudins. PNAS 101:4690-4694, 2004
  pubmed

• 7) Pazour GJ, Witman GB:The vertebrate primary cilium is a sensory organelle. Current Opinion in Cell Biology 15:105-110, 2003
  pubmed

• 8) Snell WJ, Pan J, Wang Q:Cilia and Flagella revealed:From flagellar assembly in Chlamydomonas to human obesity disorders. Cell 117:693-697, 2004
  pubmed

• 9) Guay-Woodford LM:Murine models of polycystic kidney disease:Molecular and therapeutic insights. Am J Physiol Renal Physiol 285:F1034-1049, 2003
  pubmed

• 10) Nauli SM, et al:Polycystins l and 2 mediate mechano-sensation in the primary cilium of kidney cells. Nat Genet 33:129-137, 2003

P.40 掲載の参考文献

• 1) Yu JX, Chao L, Chao J:Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distri-bution, and localization in prostate gland. J Biol Chem 269:18843-18848, 1994

• 2) Yu JX, Chao L, Chao J:Molecular cloning, tissue-specific expression, and cellular localization of human prostasin mRNA. J Biol Chem 270:13483-13489, 1995
  pubmed

• 3) Yu JX, Chao L, Ward DC, et al:Structure and chromosomal localization of the human prostasin (PRSS8) gene. Genomics 32:334-340, 1996
  pubmed

• 4) Vallet V, Chraibi A, Gaeggeler HP, et al:An epithelial serine protease activates the amiloride-sensitive sodium channel. Nature 389:607-610, 1997
  pubmed

• 5) Adachi M, Kitamura K, Miyoshi T, et al:Activation of epithelial sodium channels by prostasin in Xenopus oocytes. J Am Soc Nephrol 12:1114-1121, 2001
  pubmed

• 6) Vuagniaux G, Vallet V, Jaeger NF, et al:Activation of the amiloride-sensitive epithelial sodium channel by the serine protease mCAP1 expressed in a mouse cortical collecting duct cell line. J Am Soc Nephrol 11:828-834, 2000

• 7) Chen LM, Skinner ML, Kauffman SW, et al:Prostasin is aglycosylphosphatidylinositol-anchored active serine protease. J Biol Chem 276:21434-21442, 2001
  pubmed

• 8) Vallet V, Pfister C, Loffing J, et al:Cell-Surface Expression of the Channel Activating Protease xCAP-1 Is Re-quired for Activation of ENaC in the Xenopus Oocyte. J Am Soc Nephrol 13:588-594, 2002

• 9) Chraibi A, Vallet V, Firsov D, et al:Protease modulation of the activity of the epithelial sodium channel expressed in Xenopus oocytes. J Gen Physiol 111:127-138, 1998
  pubmed

• 10) Donaldson SH, Hirsh A, Li DC, et al:Regulation of the epithelial sodium channel by serine proteases in human airways. J Biol Chem 277:8338-8345, 2002
  pubmed

• 11) Tong Z, Illek B, Bhagwandin VJ, et al:Prostasin, a membrane-anchored serine peptidase, regulates sodium currents in JME/CF15 cells, a cystic fibrosis airway epithelial cell line. Am J Physiol:2004 (in press)

• 12) Vuagniaux G, Vallet V, Jaeger NF, et al:Synergistic Activation of ENaC by Three Membrane-bound Channel-activating Serine Proteases (mCAP1, mCAP2, and mCAP3) and Serum-and Glucocorticoid-regulated Kinase (Sgk1) in Xenopus Oocytes. J Gen Physio1120:191-201, 2002
  pubmed

• 13) Guipponi M, Vuagniaux G, Wattenhofer M, et al:The transmembrane serine protease (TMPRSS3) mutated in deafness DFNB8/10 activates the epithelial sodium channel (ENaC) in vitro. Hum Mol Genet 11:2829-2836, 2002
  pubmed

• 14) 0kumura Y, Nishikawa M, Cui P, et al:Cloning and characterization of a transmembrane-type serine protease from rat kidney, a new sodium channel activator. Biol Chem 384:1483-1495, 2003

• 15) Hughey RP, Bruns JB, Kinlough CL, et al:Epithelial Sodium Channels Are Activated by Furin-dependent Proteolysis. J Biol Chem 279:18111-18114, 2004
  pubmed

• 16) Hughey RP, Mueller GM, Bruns JB, et al:Maturation of the Epithelial Na+Channel Involves Proteolytic Processing of the α-and γ-Subunits. J Biol Chem 278:37073-37082, 2003

• 17) Narikiyo T, Kitamura K, Adachi M, et al:Regulation of prostasin by aldosterone in the kidney. J Clin Invest 109:401-408, 2002
  pubmed

• 18) Tuyen DG, Kitamura K, Adachi M, et al:Inhibition of prostasin expression by TGF-βin renal epithelial cells. Kidney Int:2004 (in press)

• 19) Iwashita K, Kitamura K, Narikiyo T, et al:Inhibition of prostasin secretion by serine protease inhibitors in the kidney. J Am Soc Nephrol 14:11-16, 2003
  pubmed

• 20) Chen LM, Chai KX:Prostasin serine protease inhibits breast cancer invasiveness and is transcriptionally regulated by promoter DNA methylation. Int J Cancer 97:323-329, 2002
  pubmed

• 21) Chen LM, Zhang X, Chai KX:Regulation of prostasin expression and function in the prostate. Prostate 59:1-12, 2004
  pubmed

• 22) Wang C, Chao J, Chao L:Adenovirus-mediated human prostasin gene delivery is linked to increased aldosterone production and hypertension in rats. Am J Physiol 284:R1031-1036, 2003

• 23) Bridges RJ, Newton BB, Pilewski JM, et al:Na+ transport in normal and CF human bronchial epithelial cells is inhibited by BAY 39-9437. Am J Physiol 281:L16-23, 2001

第2章 原因遺伝子の解明と治療の新しいコンセプト

P.44 掲載の参考文献

• 1) Ward CJ, Hogan MC, Rossetti S, et al:The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 30:259-269, 2002
  pubmed

• 2) Onuchic LF, Furu L, Nagasawa Y, et al:PKHD 1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats. Am J Hum Genet 70:1305-1317, 2002

• 3) Ward CJ, Yuan D, Masyuk TV, et al:Cellular and subcellular localization of the ARPKD protein;fibrocystin is expressed on primary cilia. Hum Mol Genet 12:2703-2710, 2003
  pubmed

• 4) Nauli SM, Alenghat FJ, Luo Y, et al:Polycystins 1 and 2 mediate mechanosensation the primary cilium of kidney cells. Nat Genet 33:129-137, 2003
  pubmed

• 5) Yoder BK, Tousson A, Millican L, et al:Polaris, a protein disrupted in orpk mutant mice, is required for assembly of renal cilium. Am J Physiol Renal Physiol 282:F541-552, 2002
  pubmed

• 6) Hou X, Mrug M, Yoder BK, et al:Cystin, a novel ciliaassociated protein, is disrupted in the cpk mouse model of polycystic kidney disease. J Clin Invest 109:533-540, 2002
  pubmed

• 7) Lin F, Hiesberger T, Cordes K, et al:Kidney-specific inactivation of the KIF3A subunit of kinesin-II inhibits renal ciliogenesis and produces polycystic kidney disease. Proc Natl Acad Sci 100:5286-5291, 2003
  pubmed

• 8) Bhunia AK, Piontek K, Boletta A, et al:PKDl Induces p21waf1 and Regulation of the Cell Cycle via Direct Activation of the JAK-STAT Signaling Pathway in a Process Requiring PKD2. Cell 109:157-168, 2002

• 9) Yamaguchi T, Nagao S, Wallace DP, et al:Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63:1983-1994, 2003
  pubmed

• 10) Nagao S, Yamaguchi T, Masatomo K, et al:Renal activa-tion of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease. Kidney lnt 63:427-437, 2003

• 11) Gattone VHII, Wang X, Harris PC, et al:Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9:1323-1326, 2003

• 12) Torres VE, Wang X, Qian Q, et al:Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10:363-364, 2004

• 13) Muto S, Aiba A, Saito Y, et al:Pioglitazone improves the phenotype and molecular defects of a targeted Pkdl mutant. Hum Mol Genet 11:1731-1742, 2002

• 14) Ubara Y, Tagami T, Sawa N, et al:Renal Contraction Therapy for Enlarged Polycystic Kidneys by Transcatheter Arterial Embolization in Hemodialysis Patients. Am J kidney Dis 39:571-579, 2002
  pubmed

• 15) Ubara Y, Takei R, Hoshino J, et al:Intravascular Embolization Therapy in a Patient With an Enlarged Polycystic Liver. Am J Kidney Dis 43:733-738, 2004

P.48 掲載の参考文献

• 1) Suzuki Y, Okada T, Higuchi A, et al:The low molecular weight of protein components in children urine. Acta Pediatr Jpn 22:1-5, 1980

• 2) Wrong OM, Norden AGW, Feest TG:Dent:s disease:a familial renal tubular syndrome with hypercalciuria, tubular proteinuria, rickets, nephrocalcinosis and eventual renal failure. Q J Med 77:1086-1087, 1990

• 3) Igarashi T, Hayakawa H, Shiraga H, et al:Hypercalciuria and nephrocalcinosis in patients with idiopathic low-molecular-weight proteinuria in Japan:is the disease identical to Dent:s disease in United Kingdom? Nephron 69:242-247, 1995
  pubmed

• 4) Fisher SE, Van Bakel I, Lloyd SE, et al:Cloning and characterization of CLCN5, the human kidney chloride channel gene implicated in Dent disease (an X-linked hereditary nephrolithiasis). Genomics 29:598-606, 1995

• 5) Lloyd SE, Pearse SHS, Fisher SE, et al:A common molecular basis for three inherited kidney stone diseases. Nature 379:445-449, 1996

• 6) Akuta N, Lloyd SE, Igarashi T, et al:Mutations of CLCN5 in Japanese children with idiopathic low molecular weight proteinuria, hypercalciuria and nephrocalcinosis. Kidney Int 52:911-916, 1997
  pubmed

• 7) Igarashi T, Gunter W, Sekine T, et al:Functional characterization of renal chloride channel, CLCN5, mutations associated with Dent:s Japan disease. Kidney Int 54:1850-1856, 1998

• 8) Igarashi T, Inatomi J, Ohara T, et al:Clinical and genetic studies of CLCN5 mutations in Japanese families with Dent's disease. Kidney Int 58:520-527, 2000
  pubmed

• 9) Takemura T, Hino S, Ikeda MT, et al:Identification of two novel mutations in the CLCN5 gene in Japanese patients with familial low molecular weight proteinuria (Japanese Dent:s disease). Am J Kidney Dis 37:138-143, 2001

• 10) 0bermuler N, Grez N, Kriz W, et al:The swelling-activated chloride channel CIC-2, the chloride channel CIC-3, and CIC-5, a chloride channel mutated in kidney stone

• 11) Moulin P, Igarashi T, Van der Smissen P, et al:Altered polarity and expression of H+-ATPase without ultrastructural changes in kidney of Dent:s disease patients. Kidney Int 63:1285-1295, 2003
  pubmed

• 12) Jouret F, Igarashi T, Gafflot F, et al:Comparative ontogeny, processing, and segmental distribution of the renal chloride channel, CIC-5. Kidney Int 65:198-208, 2004

• 13) Devuyst O, Christie PT, Courtoy PJ, et al:Intra-renal subcellular distribution of the human chloride channel, CLC-5, reveals a pathophysiological basis for Dent's disease. Hum Mol Genet 8:247-257, 1999
  pubmed

• 14) Piwon N, Gunter W, Schwake M, et al:CIC-5 CI-channel disruption impairs endocytosis in a mouse model for Dent's disease. Nature 408:369-373, 2000

• 15) Cebotaru V, et al:The CLC-5 knockout mouse model of Dent:s disease develop progressive renal failure. J Am Soc Nephrol 13:282A, 2002

• 16) Lloyd SE, Gunter W, Pearse SHS, et al:Characterization of renal chloride channnel, CLCN5, mutations in hypercalciuric nephrocalcinosis (kidney stone) disorders. Hum Mol Genet 6:1233-1240, 1997

• 17) Matsuyama T, Awazu M, Oikawa T, et al:Molecular and clinical studies of Dent:s disease in Japan:biochemical examination and renal ultrasonography do not predict carrier state. Clin Nephrol 61:231-237, 2004

• 18) Raja KA, et al:Responsiveness of hypercalciuria to thiazide in Dent:s disease. J Am Soc Nephrol 13:2938-2944, 2002
  pubmed

• disease, are expressed in distinct subpopulations of renal epithelial cells. J Clin Invest 101:635-642, 1988

P.54 掲載の参考文献

• 1) Ito H, Murakami M, Miyauchi T, et al:The incidence of cystinuria in Japan. J Urol 129:1012-1014, 1983
  pubmed

• 2) Rosenberg LE, Downing S, Durant JL, et al:biochemical evidence for three genetically distinct diseases. J Clin Invest 45:365-371, 1966
  pubmed

• 3) Dello Strologo L, Pras E, Pontesilli C, et al:Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers:a need for a new classification. J Am Soc Nephrol 13:2547-2553, 2002
  pubmed

• 4) Christensen HN:Role of amino acid transport and counter-transport in nutrition and metabolism. Physiol Rev 70:43-77, 1990

• 5) Kanai Y, Endou H:Heterodimeric amino acid transporters:molecular biology and pharmacological relevance. Curr Drug Metabol 12:339-354, 2001

• 6) Verrey F, Closs EI, Wagner CA, et al:CATs and HATs:the SLC7 family of amino acid transporters. Pflugers Arch 447:532-542, 2004
  pubmed

• 7) International Cystinuria Consortium:Non-type I cystinuria caused by mutations in SLC7A9, encoding a sub-unit (b0,+AT) of rBAT. Nat Genet 23:52-57, 1999

• 8) Chairoungdua A, Segawa H, Kim JY, et al:Identification of an amino acid transporter associated with the cystinuria-related type H membrane glycoprotein. J Biol Chem 274:28845-28848, 1999

• 9) Reig N, Chillaron J, Bartoccioni P, et al:The light subunit of system b0,+ is fully functional in the absence of the heavy subunit. EMBO J 21:4906-4914, 2002

• 10) Mizoguchi K, Cha SH, Chairoungdua A, et al:Human cystinuria-related transporter:Localization and functional characterization. Kidney Int 59:1821-1833, 2002

• 11) Kanai Y, Fukasawa Y, Cha SH, et al:Transport properties of a system y+L neutral and basic amino acid transporter:Insights into the mechanisms of substrate recognition. J Biol Chem 275:20787-20793, 2000

• 12) Palacin M, Kanai Y:The ancillary proteins of HATs:SLC3 family of amino acid transporters. Pflugers Arch 447:490-494, 2004
  pubmed

• 13) Pras E, Arber N, Aksentijevich I, et al:Locahzation of a gene causing cystinuria to chromosome 2p. Nat Genet 6:415-419, 1994
  pubmed

• 14) Calonge MJ, Gasparini P, Chillaron J, et al:Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine. Nat Genet 6:420-425, 1994
  pubmed

• 15) Calonge MJ, Volpini V, Bisceglia L, et al:Genetic heterogeneity in cystinuria:the SLC3A1 gene is linked to type I but not to type III cystinuria. Proc Natl Acad Sci USA 92:9667-9671, 1995

• 16) Bisceglia L, Calonge MJ, Totaro A, et al:Localization, by linkage analysis, of the cystinuria type III gene to chromosome 19q13.1. Am J Hum Genet 60:611-616, 1997
  pubmed

• 17) Kanai Y, Segawa H, Miyamoto K, et al:Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273:23629-23632, 1998

• 18) Feliubadalo L, Arbones ML, Manas S, et al:Slc7a9-deficient mice develop cystinuria non-I and cystine urolithiasis. Hum Mol Genet 12:2097-2108, 2003
  pubmed

• 19) Egoshi K[, Akakura K, Kodama T, et al:Identification of five novel SLC3A1 (rBAT) gene mutations in Japanese cystinuria. Kidney Int 57:25-32, 2000
  pubmed

• 20) Font MA, Feliubadalo L, Estivill X, et al:International Cystinuria Consortium. Functional analysis of mutations in SLC 7A9, and genotype-phenotype correlation in non-Type I cystinuria. Hum Mol Genet 10:305-316, 2001

• 21) Abramson J, Smirnova I, Kasho V, et al:Structure and mechanism of the lactose permease of Escherichia coli. Science 301:610-615, 2003
  pubmed

• 22) Huang Y, Lemieux MJ, Song J, et al:Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 301:616-620, 2003
  pubmed

• 23) Akakura K, Egoshi K, Ueda T, et al:The long-term out-come of cystinuria in Japan. Urol Int 61:86-89, 1998

P.58 掲載の参考文献

• 1) Paver WKA, Pauline GH:Hypertension and hyperpotassemia without renal disease in a young male. Medical Journal of Australia 2:305-306, 1964

• 2) Gordon RD, Geddes RA, Pawsey CG, et al:Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med 19:287-294, 1970

• 3) Schambelan M, Sebastian A, Rector FC Jr:Mineralocor-ticoid-resistant renal hyperkalemia without salt wasting (type ll pseudohypoaldosteronism):role o increased renal chloride reabsorption. Kidney Int 19:716-727, 1981

• 4) Take C, Ikeda K, Kurasawa T, et al:Increased chloride reabsorption as an inherited renal tubular defect in familial type H pseudohypoaldosteronism. N Engl J Med 324:472-476, 1991

• 5) Mansfield TA, Simon DB, Farfel Z, et al:Multilocus link-age of familial hyperkalaemia and hypertension, pseudohypoaldosteronism type ll, to chromosomes 1q31-42 and 17p11-q21. Nat Genet 16:202-205, 1997

• 6) Disse-Nicodeme S, Achard JM, Desitter I, et al:A new locus on chromosome 12p13.3 for pseudohypoaldo-steronism type H, an autosomal dominant form of hypertension. Am J Hum Genet 67:302-310, 2000

• 7) Wilson FH, Disse-Nicodeme S, Choate KA, et al:Human Hypertension Caused by Mutations in WNK Kinases. Science 293:1107-1112, 2001
  pubmed

• 8) Wilson FH, Kahle KT, Sabath E, et al:Molecular patho-genesis of inherited hypertension with hyperkalemia:The Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. PNAS 100:680-684, 2003

• 9) Yang CL, Angell J, Mitchell R, et al:WNK kinases regulate thiazide-sensitive Na-Cl cotransport. J Clin Invest 111:1039-1045, 2003

• 10) Kahle KT, wilson FH, Leng Q, et al:WNK4 regulates the balance between renal NaCl reabsorption and K+secretion. Nat Genet 35:372-376, 2003

• 11) Kahle KT, Gimenez I, Hassan H, et al:WNK4 regulates apical and basolateral Cl:flux in extrarenal epithelia. PNAS 101:2064-2069, 2004
  pubmed

• 12) Yamauchi K, Rai T, Kobayashi K, et al:Disease-causing mutant WNK4 increases paracellular chloride permeability and phosphorylates claudins. PNAS 101:4690-4694, 2004
  pubmed

• 13) Choate KA, Kahle KT, Wilson FH, et al:WNK1, a kinase mutated in inherited hypertension with hyperkalemia, localizes to diverse CI-transporting epithelia. PNAS 100:663-668, 2003

• 14) Zambrowicz BP, Abuin A, Ramirez-Solis R, et al:Wnk1 kinase deficiency lowers blood pressure in mice:A genetrap screen to identify potential targets for therapeutic intervention. PNAS 100:14109-14114, 2003
  pubmed

第3章 難治性腎疾患治療の新たな展開

P.64 掲載の参考文献

• 1) Tomino Y, Sakai H, Special Study Group (IgA nephropathy) on Progressive Glomerular Disease:Clinical guidelines for lmmunoglobulin A (IgA) nephropathy in Japan, second version. Clin Exp Nephrol 7:93-97, 2003

• 2) Pozzi C, Bolasco PG, Fogazzi GB, et al:Corticosteroids in IgA nephropathy:a randomized controlled trial. Lancet 353:883-887, 1999
  pubmed

• 3) Tamura S, Ueki K, Ideura H, et al:Corticosteroid therapy in patients with IgA nephropathy and impaired renal function. Clinical Nephrology 55:192-195, 2001
  pubmed

• 4) Rasche FM, Schwartz A, Keller F:Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clinical Nephrology 51:147-152, 1999

• 5) 服部謙志:IgA腎症に対する口蓋扁桃摘出術の治療効果と長期予後予測因子.日耳鼻 101:1412-1422, 1998

• 6) Hotta O, Miyazaki M, Furuta T, et al:Tonsillectomy and steroid pulse therapy significantly impact in patients with IgA nephropathy. Am J Kidney Disease 38:736-743, 2001

• 7) Hotta O, Furuta T, Chiba S, et al:Regression of IgA nephropathy:arepeat biopsy study. Am J Kidney Disease 39:493-502, 2002

• 8) Xie Y, Nishi S, Ueno M, et al:The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 63:1861-1867, 2003
  pubmed

P.69 掲載の参考文献

• 1) 東條静夫:治療予後分科会まとめ.厚生省特定疾患ネフローゼ症候群調査研究班昭和49年度研究業績,p88-89, 1975

• 2) 土肥和紘:難治性ネフローゼの総括.厚生省特定疾患進行腎障害調査研究班平成10年度研究業績,p55-65, 1999

• 3) 堺 秀人,黒川 清,斉藤喬雄ほか:難治性ネフローゼ症候群 (成人例) の診療指針-平成13年度までの調査研究より. 日腎誌 44:751-761, 2002

• 4) Shiiki H, Saito T, Nishitani Y, et al:Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney lnt 65:1400-1407, 2004

• 5) Ponticelli C, Altieri P, Scolari F, et al:Arandomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9:444-450, 1998

• 6) Cattran DC, Appel GB, Hebert LA, et al:Cyclosporine in patients with steroid-resistant membranous nephropathy:Arandomized trial. Kdney lnt 59:1484-1490, 2001

• 7) Lieberman KV, Tej ani A:A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 7:56-63, 1996

• 8) Ishikawa H:Mizoribine and mycophenolate mofetil. Curr Med Chem 6:575-597, 1999
  pubmed

• 9) Shibasaki T, Koyama A, Hishida A, et al:A randomized open-label comparative study of conventional therapy versus mizoribine only therapy in patients with steroid-resistant nephrotic syndrome (Postmarketing survey). Clin Exp Nephrol 8:117-126, 2004

• 10) Lewis EJ, Hunsicker I. G, Bain RP, et al:The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993

• 11) Brenner BM, Cooper ME, de Zeeuw D, et al:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
  pubmed

• 12) Nakao N, Yoshimura A, Morita H, et al:Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE):arandomised controlled trial. Lancet 361:117-124, 2003
  pubmed

• 13) Rayner BL, Byrne MJ, van Zyl Smit R:Aprospective clinical trial comparing the treatment of idiopathic membra-nous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin Nephro 146:219-224, 1996

• 14) Muso E, Mune F, Fujii Y, et al:Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 89:408-415, 2001

• 15) 湯村和子:免疫抑制薬.長澤俊彦,二瓶 宏,湯村和子編:膠原病血管炎の腎障害,東京医学社,東京,p246-253, 2002

P.75 掲載の参考文献

• 1) 堺 秀人,黒川 清,小山哲夫ほか:急速進行性腎炎症候群の診療指針.急速進行性糸球体腎炎診療指針作成合同委員会:日本腎臓学会誌 44:55-82, 2002

• 2) Jennette JC:Rapidly progressive crescentic glomerulo-nephritis. Kidney Int 63:1164-1177, 2003

• 3) Tidman M, Olander R, Svalander C, et al:Patients hospitalized because of small vessel vasculitides with renal involvement in the period 1975-95:0rgan involvement, anti-neutrophil cytoplasmic antibodies patterns, seasonal attack rates and fluctuation of annual frequencies. J Intern Med 244:133-141, 1998
  pubmed

• 4) Jindal KK:Management of idiopathic crescentic and diffuse proliferative glomerulonephritis:evidence-based recommendations. Kidney lnt 70 (Supple):S33-40, 1999

• 5) Adu D, Pall A, Luqmani RA, et al:Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 90:401-409, 1997
  pubmed

• 6) Haubitz M, Schellong S, Gobel U, et al:Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement:a prospective, randomized study. Arthritis Rheum 41:1835-1844, 1998
  pubmed

• 7) Booth AD, Almond MK, Bums A, et al:Outcome of ANCA-associated renal vasculitis:a 5-year retrospective study. Am J Kidney Dis 41:776-784, 2003

• 8) Jayne D, Rasmussen N, Andrassy K, et al:A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36-44, 2003
  pubmed

• 9) Nowack R, Gobel U, Klooker P, et al:Mycophenolate mofetil for maintenance therapy of Wegener:s granulo-matosis and microscopic polyangiitis:a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 10:1965-1971, 1999

• 10) Hirayama K, Kobayashi M, Hashimoto Y, et al:Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis. Am J Kidney Dis 44:57-63, 2004
  pubmed

• 11) Levy JB, Pusey CD:Crescentic glomerulonephritis. In:Brady HR, Wilcox CS, editors. Therapy in Nephrology and Hypertension. 2nd ed. Saunders, London, p177-188, 2003

• 12) Levy JB, Winearls CG:Rapidly progressive glomerulo-nephritis:what should be first-line therapy? Nephron 67:402-407, 1994

P.81 掲載の参考文献

• 1) Davies DJ, Moran JE, Niall JF, et al:Segmental necrotising glomerulonephritis with antineutrophil anti-body:possible arbovirus aetiology? Br Med J (Clin Res Ed) 285:606, 1982

• 2) Jennette JC, Falk RJ, et al:Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 (2):187-192, 1994
  pubmed

• 3) 日本腎臓学会:, 急速進行性糸球体腎炎の治療指針.日本腎臓学会誌 44 (2):55-82, 2002

• 4) 橋本博史ほか:厚生省難治性血管炎に関する調査研究.平成 10年度研究報告書:213-229, 1999

• 5) 吉田雅治ほか:厚生省難治性血管炎に関する調査研究.平成 12年度総括研究報告:229-237, 2001

• 6) Ito-Ihara T, Ono T, Nogaki F, et al:Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephrol Dial Transplant (in press)

• 7) Tuso P, Moudgil A, Hay J, et al:Treatment of antineutrophil cytoplasmic auto antibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gammaglobulin. Am J Kidney Dis 20 (5):504-508, 1992

• 8) 古庄巻史ほか:川崎病におけるγ-グロブリンの大量点滴療法.基礎と臨床 17:659-672, 1983
  Medical*Online

• 9) Newburger JW, et al:A single intravenous infusion of gamma globulin as compared with fbur infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633-1639, 1991

• 10) Luqmani RA, Bacon PA, Moots RJ, et al:Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87:671-678, 1994
  pubmed

• 11) Muso E, Ito-Ihara T, Ono T, et al:Intravenous immuno. globulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Ingect Dis (In press)

• 12) Brooks CJ, King WJ, Radford DJ, et al:L-1 beta production by human polymorphonuclear leucocytes stimulated by anti-neutrophil cytoplasmic autoantibodies:relevance to systemic vasculitis. Clin Exp Immunol 106 (2):273-279, 1996

• 13) Samuelsson A, Towers TL, Ravetch J, et al:Anti-inflamatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484-486, 2001

• 14) Basta M, Dalakas MC:High-dose intravenous immuno. globulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin lnvest 94 (5):1729-1735, 1994

• 15) Ruiz de Souza V, Carreno MP, Kaveri SV, et al:Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 25 (5):1267-1273, 1995
  pubmed

• 16) Harper L, Cockwell P, Adu D, et al:Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibod-associated vasculitis. Kidney lnt 59:1729-1738, 2001

• 17) Csernok E, Trabandt A, Muller A, et al:Cytokine profiles in Wegener:s granulomatosis:predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 42 (4):742-750, 1999
  pubmed

• 18) Kitching AR, Holdsworth SR, Tipping PG:Crescentic Glomerulonepritis a manifestation of a nephritogenic Thl response?Histol Histopathol 15 (3):993-1003, 2000

• 19) Uno K, Komiya T, Tsukamoto T, et al:Immunomodulatory effect of intravenous immunoglobulin (IVIg) therapy as reflected in the response of peripheral mononuclear cell fractions to Th1 inducible cytokines in a patient with MPO-ANCA-related glolnerulonephritis and vasculitis. Jpn J Ingect Dis (In press)

• 20) Kobayashi I, Nogaki F, Kusano H, et al:Interleukin-12 alters the physicochemical characteristics of serum and glomerular IgA and modifies glycosylation in a ddY mouse strain having high IgA levels. Nephrol Dial Transplant 17 (12):2108-2116, 2002

• 21) Kondo N, Kasahara K, Kammeyama T, et al:Intravenous immunoglobulins suppress immunoglobulin productions by suppressing Ca (?+)-dependent signal transduction through Fc gamma receptors in B lymphocytes. Scand J Immunol 40 (1):37-42, 1994

• 22) Jayne DR, Esnault VL, Lockwood CM:ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 6 (2):207-219, 1993
  pubmed

• 23) Jayne DR, Lockwood CM:Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 35:1150-1153, 1996
  pubmed

• 24) Richter C, Schnabel A, Csernok E, et al:Treatment of antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin Clin Exp Immunol 101:2-7, 1995
  pubmed

• 25) Spahn JD, Leung DY, Chan MT, et al:Mechanisms of glucocorticoid reduction in asthmatic subjects treated withintravenous immunoglobulin. J Allergy Clin Immunol 103:421-426, 1999
  pubmed

• 26) Jayne DR, Chapel H, Adu D, et al:IIltravenous immunoglobulin for ANCA-associated systemic vasculitis withpersistent disease activity. QJM 93 (7):433-439, 2000
  pubmed

• 27) Dodd RY:Infectious risk of plasma donations:relationship to safety of intravenous immune globulins. Clin Exp Immunol 104 (Suppl 1):31-34, 1996

P.87 掲載の参考文献

• 1) 藤村吉博:血小板TTPとADAMTS13変異.高久史麿ほか編:Annual Review血液2003,中外医学社,東京, p 153-162, 2003

• 2) 松本雅則,八木秀男,藤村吉博:vWF-cleaving protease/ADAMTS13.臨床血液 44:159-167, 2003

• 3) Amorosi EL, Ultmann, JE:Thrombotic thrombocytopenic purpura:Report of 16 cases and review of the literature. Medicine (Baltimore) 45:139-159, 1966

• 4) Furlan M, Robles R, Lamie B:Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87:4223-4234, 1996

• 5) Tsai HM:Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87:4235-4244, 1996
  pubmed

• 6) Furlan M, Robles R, Solenthaler M, et al:Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 89:3097-3103, 1997
  pubmed

• 7) Rose BD, George JN:Diagnosis ofthrombotic thrombocytopenic purpura-hemolytic uremic syndrome. UpToDate 12.1, Wallesley, 2004

• 8) Rose BD, Kaplan AA, George JN:Treatment of throm-botic thrombocytopenic purpura-hemolytic uremic syndrome. UpToDate 12.1, Wallesley, 2004

• 9) Niaudet P:Treatment of hemolytic uremic syndrome in children. UpToDate 12.1, Wallesley, 2004

• 10) http://www.naramed-u.ac.jp/-trans/flame.html

• 11) Medina PJ, Sipols JM, George JN:Drug-associated throm. botic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 8:286-293, 2001

• 12) Moake JL:Thrombotic microangiopathies. N Engl J Med 347:589-600, 2002
  pubmed

• 13) Calderwood SB:Clinical manifestations, diagnosis, and treatment of enterohemorrhagic Escherichia coli. UpToDate 12. 1, Wallesley, 2004

• 14) Rock GA, Shumak KH, Buskard NA, et al (Canadian Apheresis Study Group):Comparison of plasma ex-change with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325:393-397, 1991

P.91 掲載の参考文献

• 1) Schiffmann R, et al:lnfusion of α-galactosidase A reduces tissue globotriaosylceremide storage in patients with Fabry disease. Proc Natl Acad Sci USA 97:365-370, 2000

• 2) Eng CM, et al:Safety and effiicacy of recombinant human of α-galactosidase A replacement therapy in Fabry:s dis-ease. N Engl J Med 345:9-16, 2001

• 3) Eng CM, et al:Aphase 1/2 clinical trial of enzyme replacement in Fabry disease;Pharmacokinetic, substrate clearance, and Safety studies. Am J Hum Gent 68:711-722, 2001

• 4) Schiffmann R, et al:Enzyme replacement therapy in Fabry disease;A randomized controlled trial. JAMA 285:2743-2749, 2001
  pubmed

• 5) 衛藤義勝ほか:ファブリー病患者に対するα-ガラクトシダーゼA補充療法の多施設臨床試験成績.小児科臨床 56:133-143, 2003
  Medical*Online

• 6) 衛藤義勝ほか:日本人ファブリー病患者における酵素補充療法:第三相オープン試験結果.小児科診療 66:1435-1444, 2003

第4章 糸球体疾患の診断と最新治療

P.96 掲載の参考文献

• 1) 吉澤信行,尾田高志:急性糸球体腎炎症候群.荒川正昭,長澤俊彦専門編集:最新内科学大系56,中山書店,東京, p3-30, 1995

• 2) Yamakami K, Yoshizawa N, Wakabayashi K, et al:The potential role for nephritis-associated plasmin receptor in acute poststreptococcal glomerulonephritis. Methods 21 (2):185-197, 2000
  pubmed

• 3) Yoshizawa N, Yamakami K, Fujino M, et al:Nephritis-associated plasmin receptor and acute poststreptococcal glomerulonephritis:characterization of the antigen and associated immune response. J Am Soc Nephrol 15:1785-1793, 2004
  pubmed

• 4) Oda T, Yamakami K, Omasu Y, et al:Glomerular plasmin-like activity in relation to nephritis-associated plas-min receptor in acute poststreptococcal glomerulonephritis (APSGN). J Am Soc Nephrol, 2004 (in press)

• 5) 吉澤信行,山上和夫,尾田高志:急性糸球体腎炎.Year note 2003別冊SELECTED ARTICLES:739-752, 2003

• 6) Oda T, Yoshizawa N, Takeuchi A, et al:Glomerular pro-liferating cell kinetics in acute post-streptococcal glomerulonephritis (APSGN). J Pathol 183 (3):359-368, 1997

• 7) Viera NT, Rolnero MJ, Montero MK, et al:Streptococcal erythrogenic toxin B induces apoptosis and proliferation in human leukocytes. Kidney Int 59 (3):950-958, 2001

• 8) Lottenberg R, Broder CC, Boyle MD, et al:Cloning, sequence analysis, and expression in Escherichia coli of a streptococcal plasmin receptor. J Bacteriol 174 (16):5204-5210, 1992
  pubmed

• 9) Nissenson AR, Baraff LJ, Fille RN, et al:Poststreptococcal acute glomerulonephritis:fact and controversy. Ann Intern Med 91 (1):76-86, 1979

• 10) Oda T, Jung YO, Kim HS, et al:PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60:587-596, 2001

• 11) Pancholi V, Fischetti VA:A major surface protein on group A streptococci is a glyceraldehyde-3-phosphate-dehydroge-nase with multiple binding activity. J Exp Med 176 (2):415-426, 1992

• 12) Burysek L, Syrovets T, Silnmet T:The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and janus kinase (JAK) /STAT signaling pathways. J Biol Chem 277:33509-33517, 2002

• 13) Montrucchio G, Lupia E, De Martino A, et al:Plasmin promotes an endothelium-dependent adhesion of neutro-phils. Involvement of platelet activating factor and P-selectin. Circulation 93:2152-2160, 1996

• 14) Cu GA, Mezzano S, Bannan JD, et al:Immunohistochemical and serological evidence for the role of streptococcal proteinase in acute post-streptococcal glomerulonephri-tis. Kidney Int 54 (3):819-826, 1998

P.103 掲載の参考文献

• 1) 厚生省特定疾患ネフローゼ症候群調査研究班 (上田 泰班長):昭和48年度研究業績,p7, 1974

• 2) Durkan AM, Hodson EM, Willis NS, et al:Immunosupp-ressive agents in childhood nephrotic syndrome:Ameta-analysis of randomized controlled trials. Kidney Int 59:1919-1927, 2001

• 3) Tarshish P, Tobin JN, Bernstein J, et al:Prognostic significance of the early course of minimal change nephritic syndrome:Report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769-776, 1997

• 4) 松倉裕喜:微少変化型ネフローゼ症候群ステロイド治療の長期予後.日児腎誌 15 (Suppl 1):88, 2002

• 5) Iijima K, Hamahira K, Kobayashi A, et al:Immuno histochemical analysis of renin activity in chronic cyclosporine nephropathy in childhood nephrotic syndrome. J Am Soc Nephrol 11:2265-2271, 2000

• 6) Iijima K, Hamahira K, Tanaka R, et al:Riskfactor for cyclosporine-induced tabulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney lnt 61:1801-1805, 2003

• 7) Lindholm A, Kahan BD:Influence of cyclosporine pharmacokinetics, throuch concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol The 54:205-218, 1993
  pubmed

• 8) Mahalati K, Belitsky P, Sketris I, et al:Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation 68:55-62, 1999
  pubmed

P.107 掲載の参考文献

• 1) Imai H, Hamai K, Komatsuda A, et al:IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int 51:270-276, 1997
  pubmed

• 2) Nagahama K, Matsushita H, Hara M, et al:Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis 39:706-712, 2002
  pubmed

• 3) Ohtani H, Wakui H, Komatsuda A, et al:Distribution of glomerular IgG subclass deposits in malignancy-associ-ated membranous nephropathy. Nephrol Dial Transplant 19:574-579, 2004

• 4) Oliveira DB:Membranous nephropathy:an IgG4-mediated disease. Lancet 351:670-671, 1998
  pubmed

• 5) Tencer J, Torffvit O, Thysell H, et al:Urine IgG2/IgG4-ratio indicates the significance of the charge selective properties of the glomerular capillary wall for the macro-molecular transport in glomerular disease. Nephrol Dial Transplant 14:1425-1429, 1999

• 6) Saito A, Yamazaki H, Rader K, et al:Mapping rat megalin:The second cluster of ligand binding repeats contains a 46-amino acid pathogenic epitope involved in the formation ofimmune deposits in Heymann nephritis. Proc Natl Acad Sci USA 93:8601-8605, 1996

• 7) Wakui H, Imai H, Komatsuda A, et al:Circulating antibodies against a-enolase in patients with primary membranous nephropathy (MN). Clin Exp lmmunol 108:445-450, 1999

• 8) Debiec H, Guigonis V, Mougenot B, et al:Antenatal membranous glomerulonephritis due to anti-neutral endopep-tidase antibodies. New Engl J Med 346:2053-2060, 2002

• 9) Leenaerts PL, Hall BM, Van Damme BJ, et al:Active Heymann nephritis in complement component C6 deficient rats. Kidney Int 47:1604-1614, 1995
  pubmed

• 10) Montinaro V, Lopez A, Monnro R, et al:Renal C3 synthesis in idiopathic membranous nephropathy:correlation to urinary C5b-9 excretion. Kidney Int 57:137-146, 2000

• 11) Takano T, Cybulsky AV:Complement C5b-9-mediated arachidonic acid metabolism in glomerular epithelial cells. Role of cyclooxygenese-1 and-2. Am J Pathol 156:2091-2101, 2000

• 12) Cybulsky AV, Takano T, Papillon J, et al:Complement-induced phospholipase A2 activation in experimental membranous nephropathy. Kidney Int 57:1052-1062, 2000
  pubmed

• 13) 今井裕一,小山雄太:膜性腎症.内科 89:1211-1214, 2002

• 14) 湯村和子,内田啓子,川嶋 朗ほか:ループス腎炎における免疫抑制薬ミゾリビンの血中濃度の評価.腎と透析 47:705-708, 1999

P.112 掲載の参考文献

• 1) Iitaka K, Nakamura S, Moriya S, et al:Focal segmental membranoproliferative glomerulonephritis in children. Pediatr Nephrol 18:1000-1004, 2003
  pubmed

• 2) Fujigaki Y, Ohashi N, Yonemura K, et al:A mechanism for the development of subepithelial deposits in a patient with type m membranoproliferative glomerulonephritis. Nephrology (Carlton) 8:280-284, 2003

• 3) Kano K, Nishikura K, Kojima M, et al:A patient with membranoproliferative glomerulonephritis diagnosed by the third biopsy via endocapillary proliferative glomeru-lonephritis and focal membranoproliferative glomerulo-nephritis. Clin Exp Nephrol 7:157-162, 2003

• 4) Kawasaki Y, Suzuki J, Sakai N, et al:Predicting the prognosis of renal dysfunction by renal expression of alpha-smooth muscle actin in children with MPGN type 1. Am JKidney Dis 42:1131-1138, 2003
  pubmed

• 5) Yata N, Ikeda M, Ishikura K, et al:Typical MPGN with few urinary abnormalities. Am J Kidney Dis 43:918-922, 2003

• 6) Colville D, Guymer R, Sinclair RA, et al:Visual impairment caused by retinal abnormalities in mesangio-capillary ( membranoproliferative) glomerulonephritis type n ("dense deposit disease"). Am J Kidney Dis 42:E2-5, 2003

• 7) 0wen KR, Donohoe M, Ellard S, et al:Mesangiocapillary glomerulonephritis type 2 associated with familial partial lipodystrophy (Dunnigan-Kobberling syndrome). Nephron Clin Pract 96:C35-38, 2004

• 8) Iitaka K, Nakamura S, Moriya S, et al:Long-term follow-up oftype H membranoproliferative glomerulonephritis in two children. Clin Exp Nephrol 7:58-62, 2003

• 9) Muhlfeld AS, Segerer S, Hudkins K, et al:Overexpression of complement inhibitor Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis. Kidney Int 65:1214-1223, 2004

• 10) Muhlfeld AS, Segerer S, Hudkins K, et al:Deletion of the fc-gamma receptor IIb in thymic stromal lymphopoietin transgenic mice aggravates membranoproliferative glomerulonephritis. Am J Pathol 163:1127-1136, 2003
  pubmed

• 11) Kawasaki Y, Suzuki J, Sakai N, et al:Evaluation of T helper-1/-2 balance on the basis of IgG subclasses and serum cytokines in children with glomerulonephritis. Am J Kidney Dis 44:42-49, 2004
  pubmed

• 12) Johnson RJ, Hurtado A, Merszei J, et al:Hypothesis:dysregulation of immunologic balance resultingng from hygiene and socioeconomic factors may influence the epidemiology and cause of glomerulonephritis worldwide. Am J Kidney Dis 42:575-581, 2003
  pubmed

• 13) Morales JM:Hepatitis C virus infection and renal disease after renal transplantation. Transplant Proc 36:760-762, 2004
  pubmed

• 14) Alric L, Plaisier E, Thebault S, et al:Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 43:617-623, 2004
  pubmed

• 15) Bruchfeld A, Lindahl K, Stahle L, et al:Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 18:1573-1580, 2003
  pubmed

第5章 続発性腎疾患の診断と最新治療

P.117 掲載の参考文献

• 1) Hahn AW, Resink TJ, Bernhardt J, et al:Stimulation of autocrine platelet-derived growth factor AA homodimer and transforming growth factor β in vascular smooth muscle cells. Biochem Biophys Res Commun 178:1451-1458, 1991

• 2) Palmer RM, Ashton DS, Moncada S:Vascular endothelial cells synthesize NO from L-arginine. Nature 333:664-666, 1988

• 3) Arima S, Ito S:Isolated juxtaglomerular apparatus as a tool for exploring glomerular hemodynamics:application of microperfusion techniques. Exp Nephrol 8:304-311, 2000
  pubmed

• 4) Juncos LA, Ren Y, Arima S, et al:Angiotensin n action in isolated microperfused rabbit afferent arterioles is modulated by flow. Kidney lnt 49:374-381, 1996

• 5) Riser B, Varani J, Cortes P, et al:Cyclic stretching of mesangial cells up-regulates intercellular adhesion molecule-1 and leukocyte adherence:A possible new mechanism for glomerulosclerosis. Am J Pathol 158:11-17, 2001
  pubmed

• 6) Christiansen REF, Tensad O, Leh S, et al:Glomerular charge selectivity is impaired in hypertensive nephropa-thy. Nephrol Dial Transplant 19:1083-1091, 2004.

• 7) 鴨谷亮一:日本人の悪性高血圧.Modern Medicine 3:11-17, 1974

• 8) Tylicki L, Rutkowski B, Horl WH:Multifactorial determination of hypertensive nephroangiosclerosis. Kidney Blood Press Res 25:341-353, 2002
  pubmed

• 9) Jequier E:Leptin signaling, adiposity, and energy balance. Ann NY Acad Sci 987:979-988, 2002

• 10) George JN, Sadler E, Lammle B:Platelets:Thrombotic thrombocytopenic purpura. Hematology:315-334, 2002

• 11) Chobanian AV Bakris GL Black HR et al:The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure:the JNC 7 report. JAMA 289:2560-2572, 2003
  pubmed

• 12) European Society of Hypertension-European Society of Cardiology guidelines Committee:European Society of Hypertension-European Society of Cardiology guidelines for the management ofarterial hypertension. J Hypertens 21:1011-1053, 2003

• 13) Peterson JC, Adler S, Burkart JM, et al:Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123:754-762, 1995
  pubmed

• 14) 林晃一:腎保護を視点とした高血圧性臓器障害の予防治療.日本臨牀 62:135-141, 2004

P.122 掲載の参考文献

• 1) 愼野博史:糖尿病性腎症の臨床経過と病期分類.槇野博史編著:糖尿病性腎症-発症進展機序と治療 (第1版).診断と治療社,東京,p192-196, 1999

• 2) American Diabetes Association:Nephropathy in Diabetes. Diabetes Care 27 (Suppl 1):S79-83, 2004

• 3) Hayashi Y, Makino H, Ota Z:Serum and urinary concentrations of type W collagen and laminin as a marker of microangiopathy in diabetes. Diabet Med 9 (4):366-370, 1992

• 4) Hirawa N, Uehara Y, Ikeda T, et al:Urinary prostaglandin D synthase (beta-trace) excretion increases in the early stage of diabetes mellitus. Nephron 87 (4):321-327, 2001
  pubmed

• 5) Fioretto P, Steffes MW, Sutherland DE, et al:Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69, 1998
  pubmed

• 6) Bakris GL, Williams M, Dworkin L, et al:Preserving renal function in adults with hypertension and diabetes:a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36 (3):646-661, 2000

• 7) Kidney Disease Outocomes Quality Initiative (K/DOQI):K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 (5 Suppl 1):S142-158, 2004

• 8) de Zeeuw D, Remuzzi G, Parving HH, et al:Proteinuria, atarget for renoprotection in patients with type 2 diabetic nephropathy:lessons from RENAAL. Kidney Int 65 (6):2309-2320, 2004

• 9) Hovind P, Tarnow L, Rossing P, et al:Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. Kidney Int 66 (3):1180-1186, 2004
  pubmed

• 10) Chan JC, Wat NM, So WY, et al:Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes:an Asian perspective from the RENAAL study. Diabetes Care 27 (4):874-879, 2004
  pubmed

• 11) Gaede P, Vedel P, Parving HH, et al:Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria:the Steno type 2 randomised study. Lancet 353:617, 1999
  pubmed

• 12) 赤井裕輝ほか:多角的強化療法による糖尿病性腎症の寛解. 伊藤克己,浅野 泰,遠藤 仁ほか編:Annual Review腎臓2002,中外医学社,東京,p250-257, 2002

• 13) Koya D, et al:Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14 (3):439-447, 2000
  pubmed

• 14) Soulis-Liparota T, Cooper M, Papazoglou D, et al:Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40 (10):1328-1334, 1991
  pubmed

• 15) Nakamura S, Makita Z, Ishikawa S, et al:Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46 (5):895-899, 1997
  pubmed

• 16) Forbes JM, Thallas V, Thomas MC, et al:The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 17 (12):1762-1764, 2003
  pubmed

• 17) Miyata T, van Ypersele de Strihou C, Ueda Y, et al:Angiotensin II receptor antagonists and angiotensin-con-verting enzyme inhibitors lower in vitro the f () rmation of advanced glycation end products:biochemical mechanisms. J Am Soc Nephrol 13 (10):2478-2487, 2002

• 18) Lane TA, Lamkin GE, Wancewicz E:Modulation of endothelial cell expression of intercellular adhesion molecule l by protein kinase C activation. Biochem Biophys Res Commun1 61:945-952, 1989

• 19) Park CW, Kim JH, Lee JH, et al:High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent. Diabetologia 43 (12):1544-1553, 2000
  pubmed

• 20) Vlassara H, Fuh H, Donnelly T, et al:Advanced glycation end products promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1:447-456, 1995
  pubmed

• 21) Nagel T, Resnick N, Atkinson WJ, et al:Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells. JClin Invest 94:885-891, 1994

• 22) Okada S, Shikata K, Matsuda M, et al:Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52 (10):2586-2593, 2003
  pubmed

• 23) Usui H, Shikata K, Matsuda M, et al:HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 18 (2):265-272, 2003
  pubmed

• 24) Utimura R, Fujihara CK, Mattar AL, et al:Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 63 (1):209-216, 2003
  pubmed

• 25) Tanaka N, Babazono T, Saito S, et al:Association of solute carrier family 12 (sodium/chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms. Diabetes 52 (11):2848-2853, 2003
  pubmed

P.128 掲載の参考文献

• 1) Weening JJ, D' Agati VD, Schwartz MM, et al:The class fication of glomerulonephritis in systemic lupus erythe-matosus revisited. ]didney lnt 65:521, 2004

• 2) Tam LS, Li EK, Leung CB, et al:Long-term treatment of lupus nephritis with cyclosporin A. QJM 91:573, 1998
  pubmed

• 3) Radhakrishnan J, Kunis CL, D:Agati V, et al:Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 42:147, 1994
  pubmed

• 4) Austin HA, Vaugham EM, Boumpas DT, et al:Lupus membranous nephropathy:Controlled trial of prednisone, pulse cyclophosphamide and cyclosporine (abstract). JAm Soc Nephrol 11:A439, 2000

• 5) Dooley MA, Cosio FG, Nachman P, et al:Mycophenolate mofetil therapy in lupus nephritis. Clinical observations. J Am Soc Nephrol 10:833, 1999
  pubmed

• 6) 山田 明:降圧薬の多面的作用と腎保護効果-自己免疫疾患.腎と透析 57:24, 2004

• 7) Boumpas DT, Austin HA III, Vaughan EM, et al:Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741, 1992

• 8) Gourley MF, Austin HA III, Scott D, et al:Methylpred-nisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125:549, 1996
  pubmed

• 9) Illei GG, Austin HA, Crane M, et al:Combination therapy with pulse cyclophosphamide plus pulse methylpred-nisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135:248, 2001

• 10) Houssiau FA, Vasconcelos C, D:Cruz D, et al:Immuno-suppressive therapy in lupus nephritis:the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121, 2002

• 11) Contreras G, Pardo V, Leclercq B, et al:Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971, 2004
  pubmed

• 12) Flanc RS, Roberts MA, Strippoli GFM, et al:Treatment of diffuse proliferative lupus nephritis:Ameta-analysis of randomized controlled thals. Am J Kidney Dis 43:197-208, 2004

• 13) Felson DT, Anderson J:Evidence of the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis:Results of a pooled analysis. N Engl J Med 311:1528-1533, 1984
  pubmed

• 14) Bansal VK, Beto JA:Treatment of lupus nephritis:A meta-analysis of clinical trials. Am J kidney Dis 29:193-199, 1997
  pubmed

• 15) Bono L, Cameron JS, Hicks JA:The very long-term prognosis and complication of lupus nephritis and its treat-ment. OJM 92:211-218, 1999

P.133 掲載の参考文献

• 1) 細谷龍男:痛風の腎障害の発症と進展に関する研究.慈恵医大誌 94:629-649, 1979

• 2) Okabe H, Hosoya T, Hikita M, et al:Analysis of urolithi-asis in patients with gout and hyperuricemia using ultrasonography. Jpn J Rheum 9:239-244, 1999

• 3) 日本泌尿器科学会日本Endourology ESWL学会日本尿路結石症学会編:尿路結石症の疫学,尿路結石症診療ガイドライン,東京,金原出版,p17-21, 2002

• 4) Okabe H, Hosoya T, Ichida K, et al:An epidemiologic study on pathogenesis of uric acid urolithiasis. Jpn J Rheum 7:135-144, 1997

• 5) Yu TF, Gutman AB:Uric acid nephrolithiasis in gout:pre-disposing factors. Ann Intern Med 67:1133-1148, 1967

• 6) Ettinger B, Tang A, Citron JT, et al:Randomized trial of allopurinol in the prevention of calcium oxalate calculi. NEngl J Med 315:1386-1389, 1986

• 7) Mazzali M, Kanellis J, Han L, et al:Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol 282:F991-997, 2002

• 8) Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al:Mild Hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol 283:F1105-1110, 2002

• 9) Kang DH, Nakagawa T, Feng L, et al:Arole of uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888-2897, 2002

• 10) Johnson RJ, Kang DH, Feig D, et al:Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?Hypertension 41:1183-1190, 2003

• 11) Ohno I, Hosoya T, Gomi H, et al:Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 87:333-339, 2001
  pubmed

• 12) 高尿酸血症痛風の治療ガイドライン作成委員会編:腎障害合併例に対する尿酸降下薬の使用法,高尿酸血症痛風の治療ガイドライン,日本痛風核酸代謝学会,東京,p39-40, 2002

• 13) Gutman AB, Yu TF:Urinary anmonium excretion in primary gout. J Clin Invest 44:1474-1481, 1965

• 14) Stiefel M, Verberckmoes R, Ritz E:Is asymptomatic hyperuricemia in kidney failure patients in need oftherapy? Dtsch Med Wochenschr 114:964-968, 1989

• 15) Schreiner O, Wandel E, Himmelsbach F, et al:Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure:an explanation for infrequent gout episodes in chronic renal failure patients? Nephrol Dial Transplant 15:644-649, 2000
  pubmed

第6章 腎再生 腎移植

P.139 掲載の参考文献

• 1) Sainio K, Suvanto P, Davies J, et al:Glial-cell-line-derived neurotrophic factor is required for bud initiation from ureteric epithelium. Development 124:4077-4087, 1997
  pubmed

• 2) Mendelsohn C, Batourina E, Fung S, et al:Stromal cells mediate retinoid-dependent functions essential for renal development. Development 126:1139-1148, 1999
  pubmed

• 3) Vainio SJ, Uusitalo MS:Aroad to kidney tubules via the Wnt pathway. Pediatr Nephrol 15:151-156, 2000

• 4) Moriya N, Uchiyama H, Asashima A:Induction of pronephric tubules by activin and retinoic acid in presumptive ectoderm of Xenopus laevis. Develop Growth Differ 35:123-128, 1993

• 5) Nishinakamura R, Matsumoto Y, Nakao K, et al:Murine homolog of SALLI is essential for ureteric bud invasion in kidney development. Development 128:3105-3115, 2001

• 6) Kohlhase J:SALLI mutations in Townes-Brocks syndrome and related disorders. Hum Mutat 16:460-466, 2000

• 7) Kiefer SM, Ohlemiller KK, Yang J, et al:Expression of a truncated Salll transcriptional repressor is responsible for Townes-Brocks syndrome birth defects. Hum Mol Genet 12:2221-2227, 2003
  pubmed

• 8) Sato A, Matsumoto Y, Koide U, et al:Zinc finger protein sall2 is not essential for embryonic and kidney development. Mol Cell Biol 23:62-69, 2003

• 9) Parrish M, Ott T, Lance. Jones C, et al:Loss of the Sall3 gene leads to palate deficiency, abnormalities in cranial nerves, and perinatal lethality. Mol Cell Biol 24:7102-7112, 2004
  pubmed

• 10) Terada N, Hamazaki T, Oka M, et al:Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature 416:542-545, 2002
  pubmed

• 11) Ying QL, Nichols J, Evans EP, et al:Changing Potency by spontaneous fusion. Nature 416:545-548, 2002
  pubmed

• 12) Alvarez-Dolado M, Pardal R, Garcia-Verdugo JM, et al:Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature 425:968-973, 2003
  pubmed

• 13) Dekel B, Burakova T, Arditti FD, et al:Human and porcine early kidney precursors as a new source for transplantation. Nat Med 9:53-60, 2003
  pubmed

• 14) Herzlinger D, Koseki C, Mikawa T, et al:Metanephric mesenchyme contains multipotent stem cells whose fate is restricted after induction. Development 114:565-572, 1992
  pubmed

• 15) Takasato M Osafune K Matsumoto Y et al:Identifica-tion of kidney mesenchymal genes by a combination of microarray analysis and Sall1-GFP knockin mice. Mech Dev 121:547-557, 2004

P.144 掲載の参考文献

• 1) Chinzei R, Tanaka Y, Shimizu-Saito K, et al:Embryoid-body cells derived from a mouse embryonic stem cell line show differentiation into functional hepatocytes. Hepatology 36:22-29, 2002
  pubmed

• 2) Soria B, Roche E, Berna G, et al:Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes 49:157-162, 2000
  pubmed

• 3) Kim JH, Auerbach JM, Rodriguez-Gomez JA, et al:Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418:50-56, 2002

• 4) Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al:Embryonic stem cell lines derived from human blastocysts. Science 282:1145-1147, 1998
  pubmed

• 5) Schuldiner M, Yanuka O, Itskovitz-Eldor J, et al:Effects of eight growth factors on the differentiation of cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 97:11307-11312, 2000
  pubmed

• 6) Tanaka H, Terada Y, Okado T, et al:Embryoid-body derived from Wnt4-transformed mouse Embryonic stem cells Differentiate into renal tubular-like cells (投稿中)

• 7) 長田道夫:ネフロン形成の分子制御.腎と透析51 No.5:569-577, 2001

• 8) Torres M, Gomez-Pardo E, Dressler GR, et al:Pax-2 controls multiple steps of urogenital development. Development 121:4057-4065, 1995
  pubmed

• 9) Kreidberg JA, Sariola H, Loring JM, et al:WT-1 is required for early kidney development, Cell 74:679-691, 1993
  pubmed

• 10) Terada Y, Tanaka H, Okado T, et al:Expression and function of the developmental gene Wnt-4 during experimental acute renal failure in rats. J Am Soc Nephrol 14:1223-1233, 2003
  pubmed

P.149 掲載の参考文献

• 1) Weaver VM, et al:Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137:231-245, 1997
  pubmed

• 2) Wang F, et al:Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures:a different perspective in epithelial biology. Proc Natl Acad Sci USA 95:14821-14826, 1998
  pubmed

• 3) Anders M, et al:Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor. Proc Natl Acad Sci USA 100:1943-1948, 2003
  pubmed

• 4) Gurdon JB, Bourillot PY:Morphogen gradient interpretation. Nature 413:797-803, 2001
  pubmed

• 5) Thisse B, Wright CV, Thisse C:Activin-and Nodal-related factors control antero-posterior patterning of the zebrafish embryo. Nature 403:425-428, 2000
  pubmed

• 6) Hishikawa K, et al:Gene expression profile of human mesenchymal stem cells during osteogenesis in three-dimensional thermoreversible gelation polymer. Biochem Biophys Res Commun 317:1103-1107, 2004
  pubmed

• 7) Imasawa T, et al:The potential of bone marrow-derived cells to differentiate to glomerular mesangial cells. J Am Soc Nephrol 12:1401-1409, 2001
  pubmed

• 8) Xu C, et al:Feeder-free growth of undifferentiated human embryonic stem cells. Nat Biotechnol 19:971-974, 2001

• 9) Sato N, Meijer L, Skaltsounis L, et al:Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 10:55-63, 2004
  pubmed

P.153 掲載の参考文献

• 1) Bjornson CR, Rietze RL, Reynolds BA, et al:Turning brain into blood:a hematopoietic fate adopted by adult neural stem cells in vivo. Science 283:534-537, 1999

• 2) Asahara T, Murohara T, Sullivian A, et al:Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997

• 3) 0kano H, Ogawa Y, Nakamura M, et al:Transplantation ofneural stem cells into the spinal cord after injury. Semin Cell Dev Biol 14:191-198, 2003

• 4) Poulsom R, Forbes SJ, Hadivala-Dilke K, et al:Bone marrow contributes to renal paranchymal turnover and regeneration. J Pathol 195:229-235, 2002

• 5) Korbling M, Estrov Z:Adult stem cells for tissue repair A new therapeutic concept?N Engl J Med 349:570-582, 2003
  pubmed

• 6) 1masawa T, Utsunomiya Y, Kawamura T, et al:The potential of bone marrow-derived cells to differentiate to glomerular mesangial cells. J Am Soc Nephrol 12:1401-1409, 2001
  pubmed

• 7) Nishinakamura R, Matsumoto Y, Nakao K, et al:Murine homolog of SALL1 is essential for ureteric bud invasion in kidney development. Development 128:3105-3115, 2001
  pubmed

• 8) 0sumi N, Inoue T:Gene transfer into cultured mammalian embryos by electroporation. Methods 24:35-42, 2001

• 9) Eto E, Osumi-Yamashita N:Whole embryo culture and the study of postimplantation mammalian development. Develop Growth Differ 37:123-132, 1995

• 10) Miyazaki Y, Oshima K, Fogo A, et al:Bone morphogenetic protein 4 regulates the budding site and elongation of the mouse ureter. J Clin Invest 105:868-873, 2000

• 11) Watabe K, Ohashi T, Sakamoto T, et al:Rescue oflesioned adult rat spinal motoneurones by adenoviral gene trans-fer of glial cell-line derived neurotrophic factor. J Neurosci Res 60:511-519, 2000

• 12) Fiering SN, Roederer M, Nolan GP, et al:Improved FACS-Gal:flow cytometric analysis and sorting of viable eukaryotic cells expressing reporter gene constructs. Cytometry 12:291-301, 1991
  pubmed

• 13) Breunig F, Weidemann F, Beer M, et al:Fabry disease:diagnosis and treatment. Kidney lnt 84:S181-185, 2003

• 14) Barry FP:Biology and clinical applications of mesenchymal stem cells. Birth Defects Research 69:250-256, 2003
  pubmed

P.159 掲載の参考文献

• 1) 日本臨床腎移植学会,日本移植学会:腎移植臨床登録集計報告 (2004)-1,2003年実施症例の集計報告.移植 39:171-176, 2004
  Medical*Online

• 2) 打田和治:タクロリムスを用いた腎移植成績,タクロリムス 5年長期生着フォーラム,Medical Tribune 12月25日号:2003

• 3) 両角国男,武田朝美,幅 俊人ほか:特集-臓器移植の病理,腎臓移植.移植 38:14-23, 2003

• 4) 日本臨床腎移植学会,日本移植学会:腎移植臨床登録集計報告 (2003)-3,2000年追跡調査報告.移植 39:57-64, 2004
  Medical*Online

• 5) 太田和夫,高橋公太,大場 忍ほか:ABO不適合移植の一例.腎と透析 27:117-120, 1989

• 6) Takahashi K, Saito K, Takahara S, et al:Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 4:1089-1096, 2004
  pubmed

• 7) Schnitzler MA, Craig KE, Hardinger KE, et al:Mycophenolate mofetil is associated with less death with function than azathioprine in cadaveric renal transplantation. Nephrol Dial Transplant 18:1197-1200, 2003
  pubmed

• 8) Ponticelli C, Yussim A, Cambi V, et al:A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 72:1261-1267, 2001
  pubmed

• 9) Tyden G, Kumlien G, Fehrman I:Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 76:730-731, 2003
  pubmed

• 10) Ter Meulen CG, van Riemsdijk I, Hene RJ, et al:Steroid-withdrawal at 3 days after renal transplantation with anti-IL2 receptor α therapy:A prospective, randomized, multicenter study. Am J Transplant 4:803-810, 2004

• 11) Teraoka S, Sato S, Kai K, et al:Early steroid withdrawal protocol using basiliximab in kidney transplantation. Transplant Proc 36 (Suppl 2):S478-482, 2004

• 12) Eizuru Y, Minematsu T, Minamishima Y, et al:Rapid diagnosis of cytomegalovirus infections by direct immuno-peroxidase staining with human monoclonal antibody against an immediate early antigen. Microbiol lmmunol 35:1015-1022, 1991

• 13) Hirsch HH, Knowles W, Dickenmann M, et al:Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. NEJM 347:488-496, 2002
  pubmed

• 14) Kasiske BL, Snyder JJ, Matas AJ, et al:Preemptive kidney transplantation:The advantage and the advantaged. J Am Soc Nephrol 13:1358-1364, 2002
  pubmed

• 15) Ratner LE, Ciseck I. J, Moore RG, et al:Laparoscopic live donor nephrectomy. Transplantation 60:1047-1049, 1995

• 16) Wang M, Liu S, Ouyang N, et al:Protective effects of FTY7200n chronic allograft nephropathy by reducing late lymphocytic infiltration. Kidney Int 66:1248-1256, 2004
  pubmed

• 17) Kreis H, Oberbauer R, Campistol JM, et al:Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15:809-817, 2004
  pubmed

• 18) Shapiro R, Basu A, Tan H, et al:Campath (Thymoglobulin) reconditioning and tacrolimus monotherapy with subsequent weaning in renal transplantation. Abstract 142 & 144, 20th International Congress of the Transplantation Society, Vienna, 2004

• 19) Cosimi AB, Sachs DH:Mixed chimerism and transplantation tolerance. Transplantation 77:943-946, 2004
  pubmed

• 20) Cascalho M, Ogle BM, Platt JL:Xenotransplantation and the future of renal replacement. J Am Soc Nephrol 15:1106-1112, 2004
  pubmed

• 21) 高橋公太編:腎移植連絡協議会からの提言,献腎提供を増やすための取り組み-病院システムの確立を目指して-.日本医学館,東京,2002

第7章 透析・血液浄化療法の進歩

P.166 掲載の参考文献

• 1) 日本透析医学会統計調査委員会:わが国の慢性透析療法の現況2003年12月31日現在.日本透析医学会,東京,2004

• 2) Goodkin DA, Bragg-Gresham JL, Koenig KG, et al:Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and United States:The dialysis outcomes and practice patterns study (DOPPS). J Am Soc Nephrol 14:3270-3277, 2003
  pubmed

• 3) 山上征二:透析液安全基準策定報告.透析会誌 28:1487-1493, 1995

• 4) 2001,2004年度日本透析医学会学術集会コンセンサスカンファレンスにて決定され,現在論文作成中

• 5) 石森 勇,石田和寛,星野敏久ほか:内部濾過促進型血液透析器の溶質除去特性に及ぼす影響因子の検討.腎と透析 47別冊HDF療法:99:91-95, 1999

• 6) Buoncristiani U, Quintaliani G, Cozzari M, et al:Daily dialysis:long-term clinical-metabolic results. Kidney Int 33 (Suppl 24):S137-140, 1988

• 7) Buoncristiani U, Quintaliani G, et al:Dramatic improvement of clinical metabolic parameters and quality of life with daily dialysis. Int J Artif Organs 12:133-136, 1989

• 8) Buoncristiani U, Quintaliani G, Cozzari M, et al:Reversal of left ventricular hypertrophy in uremic patients by treatment with daily dialysis. Home Hemodialysis Int 1:32-36, 1997

• 9) Floridi A, Antolini F, Buoncristiani U, et al:Daily dialysis improves indices of protein glycation. Nephrol Dial Transplant 17:871-878, 2002
  pubmed

• 10) Koshikawa S, Akizawa T, Saito A, et al:Clinical effect of short daily in-center hemodialysis. Nephron Clinical Pract 95:C23-30, 2003
  pubmed

• 11) 越川昭三,斎藤 明,秋澤忠男ほか:連日透析システム (AEK-10) による連日短時間血液透析の有効性と安全性の検討 (多施設共同試験).透析会誌 12:1709-1718, 2003

• 12) Ishihara K, Tsuji T, Kurosaki T, et al:Hemocompatibility on graft copolymers composed of poly (2-methacryloy-loxyethyl phosphorylcoline) side chain and poly (n-butyl methacrylate) backbone. J Biomed Mater Res 28:225-232, 1994

• 13) Ishihara K, Fukumoto K, Miyazaki H, et al:Improvement of blood compatibility on cellulose dialysis membrane with a novel biomedical polymer having a phospholipid polar group. Artif Organs 18:559-564, 1994

• 14) Tatsumi E, Takano H, Taenaka Y, et al:Developmemt of anovel integrated heart-lung assist device-A heparincoated, preprimed, all-in-one system. ASAIO Ab:A20, 1998

• 15) Tatsumi E, Takano H, Taenaka Y, et al:Development of an ultracompact integrated heart-lung assist device. Artificial Organs 23:518-523, 1999
  pubmed

• 16) Saito A, Sugiura S, Takagi T, et al:Maintaining low concentration of plasma β 2-microglobulin with continuous slow hemofiltration. Nephrol Dial Transplant 10 (Suppl 3):52-56, 1995

• 17) Aebischer P, Ip TK, Miracoli L, et al:Renal epithelial cells grown on semipermeable processor. Trans Am Soc Artif Intern Organs 33:96-102, 1987

• 18) Aebischer P, Ip TK, Galletti PM:The bioartificial kidney:Progress toward an ultrafiltration device with renal epithelial cells processing. Life Support Sys 5:159-168, 1987

• 19) Humes HD, MacKay SM, Funke AJ, et al:Tissue engineering of a bioartificial renal tubule assist device:In vitro transport and metabolic characteristics. Kidney Int 55:2502-2514, 1999
  pubmed

• 20) Humes HD, Buffington DA, MacKay SM, et al:Replacement of renal function in uremic animals with a tissue-ngineered kidney. Nat Biotechnol 17:451-455, 1999
  pubmed

• 21) Weitzel WF, Fissell WH, Humes HD:Initial clinical experience with a human proximal tubule cell renal assist device (RAD). JAm Soc Nephrol 12 (Program and Abstracts issue):A279, 2001

• 22) Weitzel WF, Humes HD, Bartlett RH, et al:Early results with the bioartificial kidney in ICU patients with acute renal failure. J Am Soc Nephrol 13 (Program and Abstracts issue):A642, 2002

• 23) Humes HD, Weitzel WF, Swaniker FC, et al:Effect of renal cell therapy on the gene expression profiles of inflammation in patients with acute renal failure and multiorgan failure. J Am Soc Nephrol 13 (Program and abstracts Issue):A445, 2002

• 24) 0zgen N, Tarashima M, Aung T, et al:Evaluation of longterm transport ability of a bioartificial renal tubule device using LLC-PK1. Nephrol Dial Transplant 19:2198-2207, 2004

P.170 掲載の参考文献

• 1) Pacitti A, Tetta C, Mangiarotti G, et al:Beta-2-microglobulin serum profiles in different settings of mass transport and fluid pyrogen content. Kidney Int 41 (Suppl):S96-99, 1993
  pubmed

• 2) David S, Tetta C, Canino F, et al:Production of platelet activating factor by human neutrophils after backfiltration of endotoxin contaminated dialysate. ASAIO J 39:M773-777, 1993
  pubmed

• 3) 鶴澤一行ほか:透析液清浄化の臨床効果.腎と透析51 別冊ハイパフォーマンスメンブレン:185-188, 2001

• 4) 第1回九州コンセンサスカンファレンス:"透析液を置換液として使用する際の水質管理基準"の解説.九州HDF検討会会誌 1:33-42, 1995

• 5) 山上征二:透析液安全基準策定報告「水質及びパイロジェンフィルター評価基準小委員会

• 6) 森井浩世,浅野 泰,内藤秀宗,竹澤真吾:AK100-Ultraのための透析液安全基準施設基準について.透析会誌31:1107-1109, 1998

• 7) 第46回日本透析医学会コンセンサスカンファレンス「新たな透析液安全基準の設定.透析会誌 34 (Suppl):637-638, 2001

• 8) 第49回日本透析医学会コンセンサスカンファレンス「血液浄化器の新分類〜内部濾過と透析液水質による再評価.透析会誌 (in press)

• 9) 土田健司ほか:グラム陽性菌菌体成分による透析液汚染とその生物活性-慢性腎不全患者単球cytokine産生に関するET とPGの相乗効果.腎と透析38 別冊ハイパフォーマンスメンブレン:8-15, 1995

P.173 掲載の参考文献

• 1) Kawakami H, Kanamori T, Kubota S:Development of a fluorinated polyimide hollow fiber for medical devices. Journal of Artificial Organs 6:124-129, 2003
  pubmed

• 2) Iwasaki Y, Nakabayashi N, Ishihara K:In vitro and ex vivo blood compatibility study of 2-methacryloyloxyethyl phosphorylcholine (MPC) copolymer-coated hemodialysis hollow fibers. Journal of Artificial Organs 6:260-266, 2003
  pubmed

• 3) Rindi P, Pilone, N, Ricco, V, et al:Clinical experience with a new hemodiafiltration (HDF) system. ASAIO Transactions 34:765-768, 1988
  pubmed

• 4) Dellanna F, Wuepper A, Baldamus CA:Internal filtration advantage in haemodialysis?Nephrol Dial Transplant 11 (Suppl 2):83-86, 1996

• 5) Mineshima M, Ishimori I, Ishida K, et al:Effect of internal filtration on solute removal efficiency of a dialyzer. ASAIO Journal 46:456-460, 2000
  pubmed

• 6) 木村 弘,芝本 隆,高橋雅彦ほか:中空糸有効長と中空糸充填率は低分子蛋白の除去能に作用するか.日本透析医学会雑誌 36:173-178, 2003

• 7) 庭山ゆう子,廣瀬 稔,渡辺 敏ほか:膨潤糸を用いた内部濾過促進型ダイアライザの性能.医工学治療 15:3-9, 2003

• 8) 石森 勇,峰島三千男,佐藤雄一ほか:超音波ドップラーによるダイアライザ内部濾過現象の検証.医工学治療 13:187-190, 2001

• 9) Sato Y, Mineshima M, Ishimori I, et al:Effect of hollow fiber length on solute removal and quantification of internal filtration rate by Doppler ultrasound. International Journal of Artificial Organs 26:129-134, 2003
  pubmed

• 10) Poh CK, Hardy PA, Liao Z, et al:Effect of flow baffies on the dialysate flow distribution of hollow-fiber hemodialyzers:a nonintrusive experimental study using MRI. Journal of Biomechanical Engineering 125:481-489, 2003
  pubmed

• 11) Sakai Y, Wada S, Matsumoto H, et al:Nondestructive evaluation of blood flow in a dialyzer using X-ray computed tomography. Journal of Artificial Organs 6:197-204, 2003

P.178 掲載の参考文献

• 1) Cooker LA, Holmes CJ, Hoff CM:Biocompartibility of icodextrin. Kidney Int 62 (Suppl 81):S34-45, 2003

• 2) Williams JD, Craig KJ, Topley N, et al:Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephro113 (2):470-479, 2002
  pubmed

• 3) Williams JD, Craig KJ, von Ruhland C, et al:The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int (Suppl 88):S43-49, 2003
  pubmed

• 4) Moberly JB, Mujais S, Gehr T, et al:Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int 62 (suppl 81):S23-33, 2002

• 5) Mujais S, Vonesh E:Profiling of peritoneal ultrafiltration. Kidney Int 62 (Suppl 81):S17-22:2002

• 6) Vardhan A, Zweers MM, Gokal R, et al:A solution portfolio approach peritoneal dialysis. Kidney Int 62 (Suppl 81):S114-123, 2003

• 7) Ota K, Akiba T, Nakao T, et al:Peritoneal ultrafiltration and serum icodextrin concentration during dialysis with 7.5%icodextrin solution in Japanese patients. Perit Dial Int 23 (4):356-361, 2003
  pubmed

• 8) Brown EA, Davies SJ, Rutherford P, et al:Survival of functionally anuric patients in automated peritoneal dialysis the European APD Outcome Study. J Am Soc Nephrol 14 (11):2948-2957, 2003
  pubmed

• 9) Marshall J, Jennings P, Scott A, et al:Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 64 (4):1480-1486, 2003
  pubmed

• 10) Johnson DW, Arndt M, O'shea A, et al:Icodextrin as salvage therapy in peritoneal dialysis patients with refrac-tory fluid overload. BMC Nephrol 2:2, 2001

• 11) Davies SJ, Woodrow G, Donovan K, et al:Icodextrin improves the fiuid status of peritoneal dialysis patients:results of a double-blind randomized controlled trial. J Am Soc Nephrol l4 (9):2338-2344, 2003

• 12) Guo A, Wolfson M, Holt R:Early quality of life benefits of icodextrin in peritoneal dialysis. Kidney Int (Suppl 81):S72-79, 2002
  pubmed

• 13) Mistry CD, Gokal R, Peers E:A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter lnvestigation of lcodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 46 (2):496-503, 1994

• 14) Martin J, Sansone G, Cirugeda A, et al:Severe peritoneal mononucleosis associated with icodextrin use in continuous ambulatory peritoneal dialysis. Adv Perit Dial 19:191-194, 2003

• 15) Parikova A, Zweers MM, Struijk DG, et al:Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions. Adv Perit Dial 19:186-190, 2003

P.184 掲載の参考文献

• 1) Read RR, Eberwein P, Dasgupta MK, etal:Peritonitis in peritoneal dialysis:bacterial colonization by biofilm spread along the catheter surface. Kidney Int 35:614-621, 1989
  pubmed

• 2) Moncrief JW, Popovich RP, Broardrick LJ, et al:The Moncrief-Popovich catheter:a new peritoneal access technique for patients on peritoneal dialysis. ASAIO J 39:62-65, 1993

• 3) Moncrief JW, Popovich RP, Simmons E, et al:Peritoneal access technology. Perit Dial Int 13:121-123, 1993

• 4) Moncrief JW, Popovich RP, Dasgupta M, et al:Reduction in peritonitis incidence in continuous ambulatory peritoneal dialysis with a new catheter and implantation technique. Perit Dial Int 13:S329-331, 1993
  pubmed

• 5) Moncrief JW, Popovich RP, Seare W, et al:Peritoneal dialysis access technology:The Austin Diagnostic Clinic experience. Perit Dial Int 16:S327-329. 1996
  pubmed

• 6) Han DC, Cha HK, So IN, et al:Subcutaneously implanted catheters reduce the incidence of peritonitis:during CAPD by eliminating infection by periluminal route. Adv Perit Dial 8:298-301, 1992
  pubmed

• 7) Park SM, Yim AS, Chung SH, et al:Effect of prolonged subcutaneous implantation of peritoneal catheter on peritonitis rate during CAPD:Aprospective randomized study, Blood Purif 16:1710-178, 1998.

• 8) de Alvaro F, Selgas R, Bajo MA, et al:Moncrief:s technique for peritoneal catheter placement:Experience of a CAPD unit. Adv Perit Dial 10:199-202, 1994

• 9) Page DE, Turpin C:Asimple and inexpensive method of subcutaneous implantation of catheter distal segment using a Tenckhoff curled catheter. Perit Dial Int 20:85-87, 2000

• 10) 石黒 望:CAPDカテーテルの留置時期.臨床透析 17:939-944, 2001

• 11) Twardowski ZJ, Nichols WK, Nolph KD, et al:Swanneck prestermal catheter for peritoneal dialysis. Adv Perit Dial 8:316-324, 1992

• 12) 窪田 実,石黒 望,濱田千江子ほか:バスタブカテーテル (presternal catheter) の成績.腎と透析 49:59-63, 2000

• 13) Kubota M, Kanazawa M, Takahashi Y, et al:Plantation of presternal catheter using Moncrief technique:Aiming fo rfewer catheter-related complications. Perit Dial Int 21:S184-187, 2001

• 14) 窪田 実,小柳伊知朗,井尾浩章ほか:腹膜透析の新しい導入法;"Moncrief and Popovichのカテーテル挿入法"を用いた段階的導入.日本透析医学会雑誌 35:1279-1285, 2002

P.189 掲載の参考文献

• 1) Shumak KH, Rock GA:Therapeutic plasma exchange. N Engl J Med 310:762-771, 1984
  pubmed

• 2) 福井次矢:EBM (Evidence-based Medicine) と医療の質. 日本内科学会雑誌 91:3415-3420, 2002

• 3) Mcleod BC:An approach to evidence-based therapeutic apheresis. J Ther Apher 17:124-132, 2002

• 4) 篠田俊雄:血漿浄化療法血液吸着療法.透析療法合同専門委員会編:血液浄化療法ハンドブック (改訂第3版),協同医書出版,東京,p174-191, 2004

• 5) Rock GA, Shumak KH, Buskard NA, et al (Canadian Apheresis Group):Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325:393-397, 1991
  pubmed

• 6) Furlan M, Robles R, Galbusera M, et al:Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolutic-uremic syndrome. N Engl J Med 339:1578-1584, 1998
  pubmed

• 7) Tsai H-M:Lian EC-Y:Antibodies to Von Willebrand factor-cleaving protease in acute thrombotic thrombocy topenic purpura. N Engl J Med 339:1585-1594, 1998

• 8) Lewis EJ, Hunsicker LG, Lan SP, et al:Acontrolled trial of TPE therapy in severe lupus nephritis. N Engl J Med 326:1371-1379, 1992

• 9) Schroeder JO, Schwab U, Zennet R, et al:TPE and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. Preliminary results of the LPSG Trial. Arthrit Rheum 40:S326, 1997

• 10) Furuta T, Hotta O, Yusa N, et al:Lymphocytapheresis to treat rapidly progressive glomerulonephritis:a randomised comparison with steroid-pulse treatment. Lancet 352:203-204, 1998
  pubmed

• 11) Cole E, Cottran D, Magil A, et al:A prospective randomozed trial ofplasma exchange as additive therapy in idiopathic crescentic glomrulonephritis. Am J Kidney Dis 20:261-269, 1992

• 12) Muso E, Mune M, Fujii Y, et al:Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid montherapy. Nephron 89:408-415, 2001

• 13) Wang Y, Liu Y, Sarker KP, et al:Polymyxin B bind to anandamide and inhibits its cytotoxic effect. FEBS Lett 470:151-155, 2000

P.194 掲載の参考文献

• 1) Davison AM:β 2-microglobulin and amyloidosis:who is at risk?Nephrol Dial Transplant 10 (Suppl 10):48-51, 1995

• 2) Omori K, Kazama JJ, Song J, et al:Association of the MCP-1 gene polymorphism A-2518G with carpal-tunnel syndrome in hemodialysis patients. Amyloid 9:175-182, 2002
  pubmed

• 3) Naiki H, Gejyo F:Kinetic analysis of amyloid fibril formation. Methods Enzymol 309:305-318, 1999
  pubmed

• 4) Yamaguchi I, Hasegawa K, Takahashi N, et al:Apolipo-protein E inhibits the depolymerization of β 2-microglobulin-related amyloid fibrils at a neutral pH. Biochemistry 40:8499-8507, 2001

• 5) Yamamoto S, Yamaguchi I, Hasegawa K, et al:Glycosami-noglycans enhance the trifluoroethanol-induced extension of β 2-microglobulin-related amyloid fibrils at a neutral pH. J Am Soc Nephrol 15:126-133, 2004

• 6) Yamaguchi I, Suda H, Tsuzuike N, et al:Glycosaminogly-can and proteoglycan inhibit the depolymerization of β 2-microglobulin amyloid fibrils in vitro. Kidney Int 64:1080-088, 2003

• 7) Nakai S, Iseki K, Tabei K, et al:Outcomes of hemodiafil-tration based on Japanese dialysis patient registry. Am J Kidney Dis 38:S212-216, 2001

• 8) Koda Y, Nishi S, Miyazaki S, et al:Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 52:1096-1101, 1997
  pubmed

• 9) Kazama JJ, Maruyama H, Gejyo F:Reduction of circulating β 2-microglobulin level for the treatment of dialysis-related amyloidosis. Nephrol Dial Transplant 16 (Suppl 4):31-35, 2001

• 10) Abe T, Uchita K, Orita H, et al:Effect of β 2-microglobulin adsorption column on dialysis-related amyloidosis. Kidney Int 64:1522-1528, 2003

• 11) 下条文武,天野 泉,中澤了一ほか:β2-ミクログロブリン吸着器リクセルS-15およびS-35の臨床検討.透析会誌 36:117-123, 2003

• 12) 下条文武,木村秀樹,川口良人:透析アミロイド症に対する少量ステロイド治療の現況-アンケート集計結果より-.透析会誌 31:73-78, 1998

• 13) 大森健太郎,青池郁夫,青柳春樹ほか:透析皮膚掻痒症の実態-新潟県内41施設2474名の調査報告-.透析会誌 34:1469-1477, 2001

• 14) 金澤 均,大堀弘明,越川 信ほか:掻痒症軽減に対する PMMA膜 (BG-U) の臨床評価-2年間の観察-.日本血液浄化技術研究会雑誌 11:51-54, 2003

• 15) 山田智子,菅谷博之,青池郁夫ほか:痒みを有する透析患者に存在する肥満細胞脱顆粒因子の分離と透析膜による除去. 腎と透析55 (別冊):167-171, 2003

第8章 腎不全患者の予後と合併症

P.198 掲載の参考文献

• 1) Goodkin DA, Bragg-Gresham JL, Koenig KG, et al:Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States:the Dialysis Outcomes and Practice Patterns Study (DOPPS). JAm Soc Nephrol 14 (12):3270-3277, 2003

• 2) 日本透析医学会統計調査委員会:わが国の慢性透析療法の現況 (2001年12月31日現在).日本透析医学会, 2002

• 3) 井関邦敏:統計手法を用いた透析療法の評価と対策.腎不全治療マニュアル,南江堂,東京,p155-163, 2004

• 4) Allon M, Depner TA, Radeva M, et al (HEMO Study Group):Impact of dialysis dose and membrane on infection-related hospitalization and death:results of the HEMO Study. J Am Soc Nephrol 14 (7):1863-1870, 2003

• 5) Young EW, Albert JM, Satayathum S, et al:Predictors and Consequences of Altered mineral Metabolism among Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int (in Press)

• 6) Block GA, Hulbert-Shearon TE, Levin NW, et al:Association of serum phosphorus and calcium phosphate product with mortality risk in chronic hemodialysis patients:A national study. Am J Kidney Dis 31:607-617, 1998
  pubmed

• 7) Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, et al:Association of elevated serum PO4, CaXPO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephro112:2131-2138, 2001

• 8) Kimata N, Albert JM, Akiba T, et al:Association of Serum Calcium and Phosphorus with Cardiac Mortality in hemodialysis Patients:New results from the DOPPS. J Am Soc Nephrol 15:3A-4A, 2004

• 9) 平澤由平,鈴木正司,伊丹儀友ほか:血液透析患者の腎性貧血に対する遺伝子組換えヒトエリスロポエチン製剤 (rHuEPO) 治療における維持Ht値と生命予後に関する大規模調査 (rHuEPO特別調査).日本透析医学会雑誌 36 (7):1265-1272, 2003

• 10) Pifer TB, McCullough KP, Port FK, et al:Mortality risk in hemodialysis patients and changes in nutritional indi-cators:DOPPS. Kidney Int 62 (6):2238-2245, 2002

• 11) Mapes DI., Lopes AA, Satayathum S:Health-related quality of life as a predictor of mortality and hospitalization:the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 64 (1):339-349, 2003

P.200 掲載の参考文献

• 1) Fukuhara S, Lopes AA, Bragg-Gresham JL, et al:Health-related quality of life among dialysis patients on three continents:The Dialysis Outcomes and Practice Patterns Study. Kidney Int 64:1903-1910, 2003
  pubmed

• 2) Mapes DI., Lopes AA, Satayathum S, et al:Health-related quality of life as a predictor of mortality and hospitalization:The Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 64:339-349, 2003

• 3) Fukuhara S, Bito S, Green J, et al:Translation, adaptation, and validation of the SF-36 for use in Japan. J Clin Epidemiol 51:1037-1044, 1998
  pubmed

• 4) Fukuhara S, Kosinski M, Wada S, et al:Psychometric and clinical tests ofvalidity ofthe Japanese SF-36 health sur-vey. J Clin Epidemio1 51:1045-1053, 1998

• 5) 福原俊一,鈴鴨よしみ:SF-36日本語版マニュアル (version 2. 0), (非特) 健康医療評価研究機構,東京,2004 http://www.SF-36.jp

• 6) 三浦靖彦,Joseph Green,福原俊-:KDQOL-SFTM version 1.3 日本語版マニュアル,健康医療評価機構,京都, 2004

• 7) Fukuhara S, Matsumura S, Bito S, et al:Association of self-reported mental-health status with overall use of health-care resources in Japan. Quality of Life Research 8 (7):626, 1999

P.205 掲載の参考文献

• 1) Q/DOQI clinical practice guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Kidney Disease Outcome Quality lnitiative. Am J Kidney Dis 42 (supple 3):S1-147, 2003

• 2) Kinugasa E, Koshikawa S:Effects of PB-94 (sevelamer hydrochrolide), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients-A Randomised, Open Label, Dose Titration Study of PB-94 versus Caltan(R) Tablet 500 (calcium carbonate)-. J Am Soc Nephrol 12:755A, 2001

• 3) Yokel RA, et al:Alminium toxicokinetics. Pharmacol Toxicol 88:159-167, 2001

• 4) D'Haese PC, et al:A multicenter study on the effects of lanthanum carbonate (FosrenolTM) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 85 (Suppl):S73-78, 2003
  pubmed

• 5) Akizawa T, Suzuki M, Akiba T, et al:Long-term effect of 1,25-dihydroxy-22-oxavitamin D (3) on secondary hyper-parathyroidism in haemodialysis patients. One-year administration study. Nephrol Dial Transplant 17:28-36, 2002

• 6) Monier-Faugere MC, Geng Z, et al:22-oxacalcitriol suppresses sedondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int 55:821-832, 1999

• 7) Slatopolsky E, Weerts C, Thielan J, et al:Suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136-2143, 1984
  pubmed

• 8) 重松 隆:ビタミンD静注療法におけるcalcitriol と maxacalciol (22-oxacalcitriol:OCT) の差異の考慮.第13回腎とビタミンD研究会記録集,p103-105, 2002

• 9) Hayashi M, Tsuchiya Y, Itaya Y, et al:Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis:a randomized prospective multicentre trial. Nephrol Dial Transplant 19:2067-2073, 2004

• 10) Teng M, Wolf M, Lowrie E, et al:Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy. N Eng J Med 349:446-456, 2003
  pubmed

• 11) Goodman WG, Hladik GA, Turner SA, et al:The calcimimetics agant AMGO73 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017-1024, 2002

• 12) Block GA, Martin KJ, de Francisco ALM, et al:Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. N Eng J Med 350:1516-1525, 2004

• 13) Siizaki K, Hatamura I, Negi S, et al:Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induced apoptosis in uremia. Kidney lnt 64:992-1003, 2003

• 14) 富永芳博:外科的副甲状腺摘出術総論.黒川 清監修,深川雅史編集:新しい透析骨症,日本メディカルセンター, 東京,P214-223, 2003

P.208 掲載の参考文献

• 1) Macdougall IC:Erythropoetin and renal failure. Curr Hematol Res 2:459-464, 2003

• 2) Iwaki S, Suzuki R, Nomura K, et al:Oral zinc supplementation reduces mean erythropoiein (EPO) dose in EPO required hemodialysis patients. J Am Soc Nephrol 12:357A (abstract), 2001

• 3) Casadeval N, Nataf J, Viron B, et al:Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. New Eng J Med 346:469-475, 2002

• 4) Chen C, Sytowski AJ:The erythropoietin receptor and signal cascade. in Erythropoietin:Molecular Biology and Clinical Use, ed. by Wolfgang Jelkmann:FP Graham Publishing Co, USA, p165-194, 2003

• 5) Barbone FP, Johnson DL, Farrell FX, et al:New epoetin molecules and novel thrapeutic approaches. Nephrol Dial Transplant 14 (Suppl 2):80-84, 1999

• 6) Kiby SL:Gene therapy for renal anemia in mice with poly-cystic kidney using an adenovirus vector encording the human erythropoietin gene. Kidney lnt 55:1234-1240, 1999

• 7) Macdougall IC:Darbepoetin alfa:Anew therapeutic agent for renal anemia. Kidney Int 61 (Suppl 80):S55-61, 2002

• 8) Egrie JC, Dwyer E, Browne JK, et al:Darbepoetin alfa has a longer circulating half-life and greater in vitro po-tency than recombinant human erythropoietin. Experimental Hematology 31:290-299, 2003

• 9) Zamboni WC, Stewart CF:An overview of the pharmaco-kinetic disposition of darbepoetin alfa. Pharmacother 22:S133-140, 2002

• 10) Lelkmann W:The enigma of the metabolic fate of circulating erythropoietin (EPO) in view of the pharmacoki-netics of the recombinant drugs rhEPO and NESP. Eur J Haematol 69:265-274, 2002

• 11) Bailon P, Pahlke W, Brandt M, et al:CERA (Continuous Erythropoiesis Receptor Activator) for the treatment of renal anemia:a new agent with an innovative mechanism of action. Poster presentation in World Congr Nephrol, 2003

• 12) Tare N, Pill J, Hosel W, et al:Preclinical phermacodynamics and pharmacokinetics of CERA (Continuous Erythropoiesis Receptor Activator):a new erythropoietic agent for anemia management in patients with kidney disease. Poster presentation in World Congr Nephrol, 2003

• 13) Reigner B, Jordan P, Pannier A, et al:Phase I study of the new erythro-poietic agent, CERA (Continuousptor Erythropoiesis Receptor Activator):demonstration of a dose-dependent response. Poster presentation in World Congr Nephrol, 2003

• 14) Dougherty F, Reigner B, Beyer U:Dose-dependent erythrpoietic response to subcutaneous CERA (Continuous Erythropoiesis Receptor Activator) in a multipledose study of dialysis patients with chronic renal anemia. poster presentation in EDTA, 2004

• 15) Dougherty F, Leypold JK, Cheung A, et al:No effect of hemodialysis or homofiltration on concentrations of CERA (Continuous Erythropoiesis Receptor Activator):in vitro study results. Poster presentation in Am Soc Nephrol, 2003

• 16) Summers S, Matij cvic A, Almond M:Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia. Nephrol Dial Transplant 19:2137-2139, 2004

• 17) Asari A, Gokal R:Pure red cell aplasia secondary to epoetin alpha responding to darbepoetin alpha in a patient on peritoneal dialysis. J Am Soc Nephrol 15:2204-2207, 2004

P.214 掲載の参考文献

• 1) Sarnak MJ, Levery AS, Schoolwerth A, et al:Kidney disease are a risk for development of cardiovascular diseases:a statement from the American heart association council on kidney in cardiovascular disease high blood pressure research, clinical cardiology, and epideminolgy and prevention. Circulation 108:2154-2169, 2003

• 2) Foley RN, Parfrey PS, Harnett JD, et al:The impact of anemia on cardiomyopathy, morbidity and mortality in end stage renal disease. Am J Kidney Dis 28:53-61, 1996

• 3) NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease:update 2000. Am J Kidney Dis 37 (Suppl 1):S186-189, 2001

• 4) Valderrabano F, Horl WH, Jacobs C, et al:European best practice guidelines 1-4:evaluating anemia and initiating treatment. Nephrol Dial Transplant 15 (Suppl4):S8-14, 2000

• 5) 日本透析医学会:2004年版慢性血液透析患者における腎性貧血治療のガイドライン.日本透析医学会誌 37, 5巻末:1-26, 2004

• 6) Levin A, Thompson CR, Ethier J, et al:Left ventricular mass index increase in early renal disease:Impact of decline in hemoglobin. Am J Kidney Dis 34:125-134, 1999
  pubmed

• 7) Iain CM:CREATE:new strategies for early anemia management in renal insufficiency. Nephrol Dial Transplant 18 (Supp12):ii3-6, 2003

• 8) Roithnger FX, Punzengruber C:The influence of ACE-inhibitor on myocardial mass and diastolic function in chronic hemodialysis patients with adequate control of blood pressure. Clin Nephrol 42:309-314, 1994

• 9) Cannella G, Paoletti E:Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effect. Am J I (idney Dis 30:659-664, 1997

• 10) Efrati S, Zaidenstein R, Dishy V, et al:ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 40:1023-1029, 2003

• 11) Douglas SK, Gregory AN, Christina MG, et al:Longitudinal follow-up and outcomes Among a population with chronic kidney disease in a large managed care organization. Arch Intern Med l64:659-663, 2004

• 12) Lucas MF, Quereda C, Teruel JL, et al:Effect of hypertension before beginning dialysis on survival of hemodialysis patients. Am J Kidney Dis 41:814-821, 2003
  pubmed

• 13) Bakris GL, Williams M, Dworkin L, et al:Preserving renal function in adults with hypertension and diabetus:a consensus approach. Am J Kidney Dis 36:646-661, 2000

• 14) Snow V, Weiss KB, Mottur-Pilson C:The evidence base for tight blood pressure control in the management of type 2diabetes mellitus. Ann Intern Med 138:587-602, 2003

• 15) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3):S12-28, 2003

P.219 掲載の参考文献

• 1) Baynes JW, Thorpe SR:Role of oxidative stress in diabetic complications:a new perspective on an old paradigm. Diabetes 48:1-9, 1999

• 2) Miyata T, Ueda Y, Shinzato T, et al:Accumulation of alubumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure:Renal implications in the pathophysiology of pentosidine. JAm Soc Nephrol 7:1198-1206, 1996

• 3) Miyata T, Fu MX, Kurokawa K, et al:Autoxidation products of both carbohydrates and lipids are increased in uremic plasma:Is there oxidative stress in uremia? Kidney Int 54:1290-1295, 1998
  pubmed

• 4) Miyata T, van Ypersele de Strihou C, Kurokawa K, et al:Alterations in non-enzymatic biochemistry in uremia. Origin and significance of"carbonyl stress"in long-term uremic complications (review). Kidney lnt 55:389-399, 1999

• 5) Miyata T, Ueda Y, Yamada Y, et al:Carbonyl stress in uremia:Accumulation of carbonyls accelerate the formation of pentosidine, an advanced glycation end product:carbonyl stress in uremia. J Am Soc Nephrol 9:2349-2356, 1998
  pubmed

• 6) Miyata T, Kurokawa K, van Ypersele de Strihou C (Advanced glycation and lipoxidation end products):Role ofreactive carbonyl compounds generated during carbohydrate and lipid metabolism (review). J Am Soc Nephrol 11:1744-1752, 2000

• 7) Miyata T, Wada Y, Cai Z, et al:Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 51:1170-1181, 1997
  pubmed

• 8) Uchida K, Kanematsu M, Sakai K, et al:Protein-bound acrolein:potential markers for oxidative stress. Proc Natl Acad Sci USA 95:4882-4887, 1998
  pubmed

• 9) Horie K, Miyata T, Maeda K, et al:Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. JClin Invest 100:2995-3004, 1997

• 10) Pennathur S, Wagner JD, Leeuwenburgh C, et al:A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 107:853-860, 2001
  pubmed

• 11) Nakamura S, Makita Z, Ishikawa S, et al:Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46:895-899, 1997
  pubmed

• 12) Miyata T, van Ypersele de Strihou C, Ueda Y, et al:Angiotensine II receptor antagonist and angiotensine converting enzyme (ACE) inhibitor scavenge oxidative radicals and lower in vitro the formation of advanced glycation end products. J Am Soc Nephrol 13:2478-2487, 2002

• 13) Onorato JM, Jenkins AJ, Thorpe SR, et al:Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions:Mechanism of action ofpyridoxamine. J Biol Chem 275:21177-21184, 2000
  pubmed

• 14) Degenhardt TP, Alderson NL, Arrington DD, et al:Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61:939-950, 2002
  pubmed

• 15) Nangaku M, Miyata T, Sada T, et al:Anti-hypertensive agent in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 14:1212-1222, 2003

第9章 腎臓病患者における心血管病

P.224 掲載の参考文献

• 1) StPeter WL, Schoolwerth AC, McGowan T, et al:Chronic kidney disease:Issues and establishing programs and clinics for improved patient outcomes, Am J Kidney Dis 41:903-924, 2003

• 2) Culleton BF, Hemmelgarn BR:Is chronic kidney disease a cardiovascular disease risk factor?Semin Dialysis 16:95-100, 2003
  pubmed

• 3) Jurkovitz CT, Abramson JL, Vaccarino LV, et al:Association of high serum creatinine and anemia increases the risk ofcoronary events:Results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 14:2919-2925, 2003

• 4) Manjunath G, Tighiouart H, Coresh J, et al:Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 63:1121-1129, 2003
  pubmed

• 5) Weiner DE, Tighiouart H, Amin MG, et al:Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality:A pooled analysis of community-based studies. J Am Soc Nephrol 15:1307-1315, 2004
  pubmed

• 6) Weiner DE, Tighiouart H, Stark PC, et al:Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 44:198-206, 2004
  pubmed

• 7) Mann JFF, Gerstein HC, Dulau-Florea I, et al:Cardiovascular risk in patients with mild renal insufficiency. Kidney Int 63:S192-196, 2003

• 8) Segura J, Campo C, Gil P, et al:Development of chronic kidney disease and cardiovascular prognosis in essential hypertension. J Am Soc Nephrol 15:1616-1622, 2004
  pubmed

• 9) Levin A, Djurdjev O, Barrett B, et al:Cardiovascular disease in patients with chronic kidney disease:Getting to the matter. Am J Kidney Dis 38:1398-1407, 2001

• 10) Shlipak MG, Fried LF, Crump C, et al:Cardiovascular disease risk status in elderly persons with renal insuff ciency. Kidney Int 62:997-1004, 2002

• 11) Cheung AK, Sarnak ML, Yan G, et al:Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58:353-362, 2000
  pubmed

• 12) Mcclellan WM, Langston RD, Presley R:Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol 15:1912-1919, 2004

• 13) Zoccali C, Mallamaci F, Tripepi G:Traditional and emergng cardiovascular risk factors in end-stage renal disease. Kidney Int 63:S105-110, 2003

• 14) De Nicola L, Minutolo R, Bellizzi V, et al:Achievement of target blood pressure in chronic kidney disease:A salty question?Am J Kidney Dis 43:782-795, 2004
  pubmed

• 15) Laradat MI, Molitoris BA:Cardiovascular disease in patients with chronic kidney disease. Semin Nephrol 22:459-473, 2002

P.229 掲載の参考文献

• 1) National Kidney Foundation:K/DOQI clinical practice guidelines for chronic kidney disease:evaluation, classification and stratification. Am J Kidney Dis 39:S1-266, 2002
  pubmed

• 2) Levin A, Djurdjev O, Barrett B, et al:Cardiovascular disease in patients with chronic kidney disease:getting to the heart of the matter. Am J Kidney Dis 38:1398-1407, 2001

• 3) Taal MW, Brenner BM:Evolving strategies for renoprotection:non-diabetic chronic renal disease Curr Opin Nephrol Hypertens 10:523-531, 2001
  pubmed

• 4) Klag MJ, Whelton PK, Randall BL, et al:Blood pressure and end-stage renal disease in men. N Engl J Med 334:13-18, 1996

• 5) Peterson JC, Adler S, Burkart JM, et al:The Modification of Diet in Renal Disease Study Group:Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study Ann Intern Med 123:754-762, 1995

• 6) Klahr S, Levey AS, Beck GJ, et a:The effects of dietary protein restriction and blood-pressure control on the pro-gression of chronic renal disease. Modification of diet in renal disease study group. N Engl J Med 330:877-884, 1994

• 7) Lewis EJ, Hunsicker LG, Bain RP, et al (The collaborative study group):The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med) 329:1456-1462, 1993

• 8) Brenner BM, Cooper ME, de Zeeuw D, et al:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
  pubmed

• 9) Lewis EJ, Hunsicker LG, Clarke WR, et al:Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
  pubmed

• 10) Agodoa LY, Appel L, Bakris GL, et al:Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA 285:2719-2728, 2001
  pubmed

• 11) Wright JT, Bakris G, Greene T, et al:Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 288:2421-2431, 2002
  pubmed

• 12) Mann JF, Gerstein HC, Pogue J, et al:Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril:the HOPE randomized trial. Ann Intern 134:629-636, 2001
  pubmed

• 13) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2000年版,日本高血圧学会,東京,2000

• 14) The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993

• 15) UK Prospective Diabetes Study (UKPDS) Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998

• 16) UK Prospective Diabetes Study (UKPDS) Group:Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
  pubmed

• 17) Kimura G, Imanishi M, Sanai T, et. al:Intrarenal hemodynamics in patients with essential hypertension. Circ Res 69:421-428, 1991

• 18) Imanishi M, Yoshioka K, Okumura M, et al:Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early disbetic nephropathy. Kidney Int 63 (Suppl):S198-200, 1997

• 19) Anderson S, Rennke HG, Garcia DL, et al:Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 36:526-536, 1989

• 20) The EUCLID study group:Randomised placebo-controlled trial of lisinopril in normotensive patients with insulindependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349:1787-1792, 1997
  pubmed

• 21) Parving HH, Lehnert H, Brochner-Mortensen J, et al:The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
  pubmed

• 22) Heart Outcomes Prevention Evaluation Study lnvestigators:Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus:results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
  pubmed

• 23) Mathiesen ER, Hommel E, Giese J, et al:Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 303:81-87, 1991
  pubmed

• 24) Fukuda M, Munemura M, Usami T, et al:Nocturnal blood pressure is elevated with natriuresis and proteinuria as renal function deteriorates in nephropathy. Kidney Int 65:621-625, 2004
  pubmed

P.233 掲載の参考文献

• 1) Safian RD, Textor SC:Renal-artery stenosis. N Engl J Med 344:431-442, 2001
  pubmed

• 2) Caps MT, Perissinotto C, Zierler RE, et al:Prospective study of atherosclerotic disease progression in the renal artery. Circulation 98 (25):2866-2872, 1998
  pubmed

• 3) Luscher TF, Lie JT, Stanson AW, et al:Arterial fibromus-cular dysplasia. Mayo Clin Proc 62 (10):931-952, 1987

• 4) Kaplan NM:in Clinical Hypertension, 8th ed, Williams &Wilkins, Baltimore, p381-403, 2002

• 5) Woodrow G, Cook JA, Brownjohn AM, et al:Is renal vas-culitis increasing in incidence?Lancet 336 (8730):1583, 1990

• 6) Ward MM, Studenski S:Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. Arch Intern Med 152 (10):2082-2088, 1992
  pubmed

• 7) Riccialdelli L, Arnaldi G, Giacchetti G, et al:Hypertension due to renal artery occlusion in a patient with antiphospholipid syndrome. Am J Hypertens 14 (1):62-65, 2001

• 8) Rackson ME, Lossef SV, Sos TA:Renal artery stenosis in patients with aortic dissection:increased prevalence. Radiology 177 (2):555-558, 1990
  pubmed

• 9) Yamada I, Himeno Y, Matsushima Y, et al:Renal artery lesions in patients with moyamoya disease:angiographic findings. Stroke 31 (3):733-773, 2000
  pubmed

• 10) de Zeeuw D, Donker AJ, Burema J, et al:Nephroptosis and hypertension. Lancet 1 (8005):213-215, 1977
  pubmed

• 11) Valabhji J, Robinson S, Poulter C, et al:Prevalence of renal artery stenosis in subjects with type 2 diabetes and coexistent hypertension. Diabetes Care 23 (4):539-435, 2000
  pubmed

• 12) Muller FB, Sealey JE, Case DB, et al:The captopril test for identifying renovascular disease in hypertensive patients. Am J Med 80 (4):633-644, 1986
  pubmed

• 13) 0ei HY, Geyskes GG, Mees EJ, et al:The significance of captopril renography in the diagnosis in renovascular hypertension. Contrib Nephro 156:95-103, 1987

• 14) Karanikas G, Becherer A, Wiesner K, et al:ACE inhibition is superior to angiotensin receptor blockade for renography in renal artery stenosis. Eur J Nucl Med Mol Imaging 29 (3):312-318, 2002
  pubmed

• 15) Pedersen EB:New tools in diagnosing renal artery stenosis. Kidney Int 57 (6):2657-2677, 2000
  pubmed

• 16) Caridi JG, Stavropoulos SW, Hawkins IF Jr:CO2 digital subtraction angiography for renal artery angioplasty in high-risk patients. AJR Am J Roentgenol 173 (6):1551-1556, 1999
  pubmed

• 17) McLaughlin K, Jardine AG, Moss JG:ABC of arterial and venous disease. Renal artery stenosis. BMJ 320 (7242):1124-1127, 2000
  pubmed

• 18) Abe K:Retrospective evaluation of surgical curability of renovascular hypertension. Jpn Circ J 39:775-777, 1975
  pubmed

• 19) Tuttle KR:Ischemic nephropathy, Curr Opin Nephrol Hypertens 10:167-173, 2001
  pubmed

• 20) Jacobson HR:Ischemic renal disease:an overlooked clinical entity? Kidney Int 34 (5):729-743, 1988
  pubmed

• 21) Conlon PJ, Athirakul K, Kovalik E, et al:Survival in renal vascular disease. J Am Soc Nephrol 9 (2):252-256, 1998
  pubmed

• 22) Luscher TF, Lie JT, Stanson AW, et al:Arterial fibromuscular dysplasia. Mayo Clin Proc 62 (10):931-529, 1987
  pubmed

• 23) Geyskes GG:Treatment of renovascular hypertension with percutaneous transluminal renal angioplasty. Am J Kidney Dis 12 (4):253-265, 1988
  pubmed

• 24) Novick A, Scoble J, Hamilton G (edited by Novick AC, Scoble J, Hamilton G):in Renal Vascular Disease HBJ College&School Division, London, p303-314, 1996

• 25) Blum U, Krumme B, Flugel P, et al:Treatment of ostial renal artery stenosis with vascular endoprosthesis after unsuccessful balloon angioplasty. N Engl J Med 336:459-465, 1997
  pubmed

• 26) van de Ven PJ, Beutler JJ, Kaatee R, et al:Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int 53 (4):986-993, 1998
  pubmed

• 27) Losito A, Gaburri M, Errico R, et all Survival of patients with renovascular disease and ACE inhibition. Clin Nephrol 52 (6):339-343, 1999
  pubmed

• 28) Johansen TL,Kjaer A:Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. BMC Nephrol 2 (1):1, 2001

• 29) Texter SC:Ischemic nephropathy:where are we now?J Am Soc Nephrol 15:1974-1982, 2004

• 30) Krijnen P, van Jaarsveld BC, Steyerberg EW, et al:A clinical prediction rule for renal artery stenosis. Ann Intern Med 129:705-711, 1998
  pubmed

• 31) Coen G, Manni M, Giannoni MF, et al:Ischemic nephropathy in an elderly nephrologic and hypertensive population. Am J Nephrol 18:221-227, 1998

• 32) Hansen KJ, Edwards MS, Craven TE, et al:Prevalence ofrenovascular disease in the elderly:A population based study. J Vasc Surg 36:443-451, 2002

• 33) Conlon PJ, 0:Riordan E, Kalra PA:Epidemiology and clinical manifestations of atherosclerotic renal artery stenosis. Am J Kidney Dis 35:573-587, 2000

• 34) Rihal CS, Textor SC, Breen JF, et al:Incidental renal artery stenosis among a prospective cohort of hypertensive patients undergoing coronary angiography. Mayo Clin Proc 77:309-316, 2002
  pubmed

• 35) Gosset J, Olin JW:Atherosclerotic renovascular disease:Clinical clues and natural history. J Endovasc Surg 4:316-320, 1997
  pubmed

• 36) Conlon PJ, Little MA, Pieper K, et al:Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int 60:1490-1497, 2001
  pubmed

• 37) Wright JR, Shurrab AE, Cheung C, et al:A prospective study ofthe determinants ofrenal functional outcome and mortality in atherosclerotic renovascular disease. Am J Kidney Dis 39:1153-1161, 2002

• 38) Alcazar JM, Rodicio JL:Ischemic Nephropathy:Clinical characteristics and treatment. Am J Kidney Dis 36:883-893, 2000
  pubmed

• 39) Mikhail A, Scoble JE:Progressive renal dysfunction despite successful renal artery angioplasty in a single kidney. Lancet 349:926, 1997

• 40)Radermacher J, Chavan A, Bleck J, et al:Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 344:410-417, 2001
  pubmed

• 41) Textor SC:Revascularization in atherosclerotic renal artery disease. Kidney Int 53:799-811, 1998
  pubmed

• 42) Connolly JO, Higgins RM, Walters HL, et al:Presentation, clinical features and outcome in different patterns of atherosclerotic renovascular disease. Q J Med 87:413-421, 1994

• 43) Topol EJ, Yadav JS:Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101:570-580, 2000
  pubmed

P.238 掲載の参考文献

• 1) Scolari F, Tardanico R, Zani R, et al:Cholesterol crystal embolism:arecognizable cause of renal disease. Am J Kidney Dis 36:1089-1109, 2000
  pubmed

• 2) Scolari F, Bracchi M, Valzorio B, et al:Cholesterol atheromatous embolism;an increasingly recognized cause of acute renal failure. Nephrol Dial transplant 11:1607-1612, 1996
  pubmed

• 3) Ramirez G, 0:Neill WM Jr, Lambert R, et al:Cholesterol embolization:acomplication of angiography. Arch Internal Med 138:1430-1432, 1978

• 4) Fukumoto Y, Tsutsui H, Tsuchihashi M, et al:The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization:a prospective study. J Am Coll Cardiol 42:211-216, 2003
  pubmed

• 5) Stabellini N, Rizzioli E, Trapassi MR, et al:Renal cholesterol microembolism:is steroid therapy effective? Nephron 86:239-240, 2000
  pubmed

• 6) Mann SJ, Sos TA:Treatment of atheroembolization with corticosteroids. Aln J Hypertens 14:831-834, 2001

• 7) Vacher-Coponat H, Pache X, Dussol B, et al:Pulmonary-renal syndrome responding to corticosteroids:consider cholesterol embolization. Nephrol Dial Transplant 12:1977-1979, 1997
  pubmed

• 8) Graziani G, Santostasi S, Angelini C, et al:Corticosteroids in cholesterol emboli syndrome. Nephron 87:371-373, 2001
  pubmed

• 9) Nakahama H, Sakaguchi K:Small dose oral corticosteroid treatment rapidly improved renal function in a patient with an acute aggravation of chronic renal failure due to cholesterol embolism. Nephrol Dial Transplant 16:872-873, 2001

• 10) Scolari F, Ravani P, Pola A, et al:Predictors of renal and patients outcomes in atheroembolic renal disease:apro-spective study. J Am Soc Nephrol 14:1584-1590, 2003

• 11) Woolfson RG, Lachman H:Improvement in renal cholesterol emboli syndrome after simvastatin. Lancet 351:1331-1332, 1998

第10章 Renin Angiotensin Aldosteron System(RAAS)と腎炎

P.242 掲載の参考文献

• 1) Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al:Inflammation and angiotensin H. Int J Biochem Cell Biol 35:881-900, 2003

• 2) Suzuki Y, Ruiz-Ortega M, Gomez-Guerrero C, et al:Angiotensin H, the immune system and renal diseases:another road for RAS?Nephrol Dial Transplant 18:1423-1426, 2003

• 3) Mezzano SA, Ruiz-Ortega M, Egido J:Angiotensin II and renal fibrosis. Hypertension 38:635-638, 2001
  pubmed

• 4) Gaedeke J, Peters H, Noble NA, et al:Angiotensin II, TGF-beta and renal fibrosis. Contrib Nephrol 135:153-160, 2001
  pubmed

• 5) Mise N, Kimura K, Kurabayashi M, et al:Angiotensin II enhances glomerular expression of a nonmuscle myosin heavy chain, SMemb, With extracellular matrix accumulation. Nephron 90:477-483, 2002
  pubmed

• 6) Matsumoto K, Morishita R, Moriguchi A, et al:Prevention of renal damage by angiotensin ll blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. Hypertension 34:279-284, 1999

• 7) Lassila M, Cooper ME, Jandeleit-Dahm K:Antipro-teinuric Effect of RAS Blockade:New Mechanisms. Curr Hypertens Rep 6:383-392, 2004

• 8) Becker BN, Yasuda T, Kondo S, et al:Mechanical stretch/relaxation Stimulates a cellular renin-angiotensin system in cultured rat mesangial cells. Exp Nephrol 6:57-66, 1998
  pubmed

• 9) Durvasula RV, Petermann AT, Hiromura K, et al:Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 65:30-39, 2004
  pubmed

• 10) Langham RG, Kelly DJ, Cox AJ, et al:Angiotensin H-induced proteinuria and expression of the podocyte slit pore membrane protein, nephrin. Nephrol Dial Transplant 19:262-263, 2004

• 11) Endlich N, Sunohara M, Nietfeld W, et al:Analysis of differential gene expression in stretched podocytes:osteopontin enhances adaptation of podocytes to mechanical stress. FASEB J 16:1850-1852, 2002
  pubmed

• 12) Remuzzi A, Gagliardini E, Donadoni C, et al:Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 62:885-894, 2002
  pubmed

• 13) Hoffmann S, Podlich D, Hahnel B, et al:Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 15:1475-1487, 2004
  pubmed

• 14) Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, et al:Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension:all for one and one for all. Am J Physiol Renal Physiol 286:F606-616, 2004

• 15) Wolf G, Ziyadeh FN, Thaiss F, etal:Angiotensin H stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2receptor. J Clin Invest 100:1047-1058, 1997

• 16) Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, et al:Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 161:430-439, 1998
  pubmed

• 17) Hisada Y, Sugaya T, Yamanouchi M, et al:Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J Clin Invest 103:627-635, 1999

• 18) Suzuki Y, Gomez-Guerrero C, Shirato I, et al:Pre-existing glomerular immune complexes induce polymorphonuclear cell recruitment through an Fc receptor-depen-dent respiratory burst:potential role in the perpetuation of immune nephritis. J Immunol 170:3243-3253, 2003

• 19) Suzuki Y, Shirato I, Okumura K, et al:Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis. Kidney Int 54:1166-1174, 1998
  pubmed

• 20) Boyce NW, Holdsworth SR:Intrarenal hemodynamic alterations induced by anti-GBM antibody. Kidney Int 31:8-14, 1987
  pubmed

• 21) Suzuki Y, Gomez-Guerrero C, Shirato I, et al:Susceptibility to T cell-mediated injury in immune complex disease is linked to local activation of renin-angiotensin system:the role of NF-AT pathway. J lmmunol 169:4136-4146, 2002

• 22) Ren K, Van Liew JB, Noble B:The effect of cyclosporin A on disease progression in proliferative immune complex glomerulonephritis. Clin lmmunol lmmunopathol 66:107-113, 1993
  pubmed

• 23) Shao J, Nangaku M, Miyata T, et al:Imbalance of T-cell subsets in angiotensin n-infused hypertensive rats with kidney injury. Hypertension 42:31-38, 2003

• 24) Suzuki H, Yamamoto T, Ikegaya N, et al:Dietary salt intake modulates progression of antithymocyte serum nephritis through alteration of glomerular angiotensin II receptor expression. Am J Physiol Renal Physiol 286:F267-277, 2004
  pubmed

P.248 掲載の参考文献

• 1) Okada H, Strutz F, Danofr TM, et al:Possible mechanisms of renal fibrosis. Contrib Nephrol 118:147-154, 1996

• 2) Miyata T, van Ypersele de Strihou C, Ueda Y, et al:Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products:biochemical mechanisms. J Am Soc Nephrol 13:2478-2487, 2002
  pubmed

• 3) Navar LG, Nishiyama A:Why are angiotensin concentrations so high in the kidney?Curr Opin Nephrol Hypertens 13:107-115, 2004
  pubmed

• 4) Taal MW, Brenner BM:Renoprotective benefits of RAS inhibition:from ACEI to angiotensin II antagonists. Kidney Int 57:1803-1817, 2000
  pubmed

• 5) Johnson DW, Saunders HJ, Vesey DA, et al:Enalaprilat directly ameliorates in vitro cyclosporin nephrotoxicity in human tubulo-interstitial cells. Nephron 86:473-481, 2000
  pubmed

• 6) Jiang B, Xu S, Hou X, et al:Temporal control of NF-kappaB activation by ERK differentially regulates interleukin-1beta-induced gene expression. J Biol Chem 279:1323-1329, 2004
  pubmed

• 7) Schuttert JB, Liu MH, Gliem N, et al:Human renal fibroblasts derived from normal and fibrotic kidneys show differences in increase of extracellular matrix synthesis and cell proliferation upon angiotensin n exposure. Pflugers Arch 446:387-393, 2003

• 8) Okada H, Watanabe Y, Kobayashi T, et al:Angiotensin II Type 1 and Type 2 Receptors Reciprocally Modulate Pro-inflammatory/Pro-Fibrotic Reactions in Activated Splenic Lymphocytes. Am J Nephrol 24:322-329, 2004
  pubmed

• 9) 0kada H, Inoue T, Kanno Y, et al:Interstitial fibroblastlike cells express renin-angiotensin system components in a fibrosing murine kidney. Am J Pathol 160:765-772, 2002

• 10) 0kada H, Watanabe Y, Inoue T, et al:Angiotensin II type lreceptor blockade attenuates renal fibrogenesis in an immune-mediated nephritic kidney through counter-activation of angiotensin II type 2 receptor. Biochem Biophys Res Commun 314:403-408, 2004

• 11) Zoja C, Binigni A, Remuzzi G:Cellular responses to protein overload:key event in renal disease progression. Curr Opin Nephrol Hypertens 13:31-37, 2004
  pubmed

• 12) Shao J, Nangaku M, Miyata T, et al:Imbalance of T-cell subsets in angiotensin H-infused hypertensive rats with kidney injury. Hypertension 42:31-38, 2003

• 13) Yang J, Dai C, Liu Y:Hepatocyte growth factor gene therapy and angiotensin H blockade synergistically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol 13:2464-2477, 2002

• 14) Manotham K, Tanaka T, Matsumoto M, et al:Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 15:1277-1288, 2004

• 15) Nishida M, Fujinaka H, Matsusaka T, et al:Absence of angiotensin ll type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest 110:1859-1868, 2002

• 16) Cordonnier DJ, Pinel N, Barro C, et al:Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. JAm Soc Nephrol 10:1253-1263, 1999

• 17) Nakao N, Yoshimura A, Morita H, et al:Combination treatment of angiotensin-nreceptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease:arandomised controlled trial. Lancet 361:117-124, 2003

• 18) Klahr S, Morrissey JJ:Comparative study of ACE inhibitors and angiotensin n receptor antagonists in interstitial scarring. Kidney Int (Suppl 63):S111-114, 1997

• 19) 0kada H, Watanabe Y, Kikuta T, et al:Bradykinin decreases plasminogen activator inhibitor-1 esxpression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme inhibition. J Am Soc Nephrol 15:2404-2413, 2004

• 20) Brown NJ, Agirbasli M, Vaughan DE:Comparative effect of angiotensin-converting enzyme inhibition and angiotensin H type l receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 34:285-290, 1999

P.254 掲載の参考文献

• 1) Hatakeyama H, Miyamori I, Fujita T, et al:Vascular al-dosterone. Biosynthesis and a link to angiotensin III-in-duced hypertrophy ofvascular smooth muscle cells. J Biol Chem 269:24316-24320, 1994

• 2) Silvestre J-S, Robert V, Heymes C, et al:Myocardial production of aldosterone and corticosterone in the rat. J Biol Chem 273:4883-4891, 1998

• 3) Gomez-Sanchez CE, Zhou MY, Cozza EN, et al:Aldosterone biosynthesis in the rat brain. Endocrinol 138:3369-3373, 1997

• 4) 武藤重明:アルドステロン作用のメディエーター.腎疾患-states of arts 2003-2004,浅野 泰,小山哲夫編:医歯薬出版,東京,p91-93, 2003

• 5) Losel RM, Feuring M, Falkenstein E, et al:Nongenomic effects of aldosterone:cellular aspects and clinical impli-cations. Steroids 67:493-498, 2002

• 6) Ebata S, Muto S, Okada K, et al:Aldosterone activates Na+/H+exchange in vascular smooth muscle cells by nongenomic and genomic mechanisms. Kidney Intern 56:1400-1412, 1999

• 7) Moellic CL, Ouvrard-Pascaud A, Capurro C, et al:Early nongenomic events in aldosterone action in renal collecting duct cells:PKCα activation, mineralocorticoid receptor phosphorylation, and cross-talk with the genomic response. J Am Soc Nephrol 15:1145-1160, 2004

• 8) Brewster UC, Perazella MA:The renin-angiotensin-aldosterone system and the kidney:effects on kidney disease. Am J Med 116:263-272, 2004
  pubmed

• 9) Juknevicious I, Segal Y, Kren S, et al:Effect of aldosterone on renal transforming growth factori?. Am J Physiol renal Physiol 286:F1059-1062, 2004

• 10) Iglarz M, Touyz RM, Viel EC, et al:Involvement of oxidative stress in the profibrotic action of aldosterone. Am JHypertens 17:597-603, 2004
  pubmed

• 11) Rocha R, Chander PN, Khanna K, et al:Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertens 31:451-458, 1998

• 12) Feria I, Pichardo I, Juarez P, et al:Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Intern 63:43-52, 2003

• 13) Brown NJ, Nakamura S, Ma L, et al:Aldosterone modulates plasminogen activator Inhibitor-1 and glomerulosclerosis in vivo. Kidney Intern 58:1219-1227, 2000

• 14) Blasi ER, Rocha R, Rudolph AE, et al:Aldsoterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Intern 63:1791-1800, 2003

• 15) Fujisawa G, Okada K, Muto S, et al:Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Intern 66:1493-1502, 2004

• 16) Takeda Y, Yoneda T, Demura M, et al:Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinol 141:1901-1904, 2000

• 17) 古松慶之,勝二達也,和田 晃ほか:RAASに対するTriple blockadeによる腎炎治療の可能性.日腎会誌 46:158, 2004

• 18) 木下卓哉,阿部克成,宮崎正信ほか:ヒト腎組織におけるアルドステロン合成酵素遺伝子 (CYP11B2) の発現について. 日腎会誌 46:258, 2004

• 19) Sato A, Saruta T:Aldosterone escape during angiotensinconverting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 29:12-21, 2001

• 20) Sato A, Hayashi K, Naruse M, et al:Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertens 41:64-68, 2003

• 21)Yu HCM, Burrell LM, Black MJ, et al:Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circ 98:2621-2628, 1998

P.258 掲載の参考文献

• 1) Mukai Y, Shimokawa H, Motoba T, et al:Involvement of Rho-kinase in hypertensive vascular disease:a novel therapeutic target in hypertension. FASEB J 15:1062-064, 2001

• 2) Uehata M, Ishizaki T, Saito H, et al:Calciuln sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389:990-994, 1997

• 3) Aikawa R, Komuro I, Yamazaki T, et al:Rho family small Gproteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. Circ Res 84:458-466, 1999

• 4) Krepinsky JC, Ingram AJ, Tang D, et al:Nitric oxide in-hibits stretch-induced MARK activation in mesangial cells through RhoA inactivation. J Am Soc Nephrol 14:2790-2800, 2003

• 5) Asano T, Suzuki T, Tsuchiya M, et al:Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase. Br J Pharmacol 98:1091-1100, 1989
  pubmed

• 6) Cavarape A, Endlich N, Assaloni R, et al:Rho-kinase inhibition blunts renal vasoconstriction induced by distinct signaling pathways in vivo. J Am Soc Nephrol 14:37-45, 2003
  pubmed

• 7) Kanda T, Wakino S, Hayashi K, et al:Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney lnt 64:2009-2019, 2003

• 8) Nishikimi T, Akimoto K, Wang X, et al:Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl saltsensitive rats. J Hypertens 22:1787-1796, 2004
  pubmed

• 9) Moriyama T, Nagatoya K:The Rho-ROCK system as a new therapeutic target for preventing interstitial fibrosis. Drug News Perspect 17:29-34, 2004
  pubmed

• 10) Hall A:Rho GTPases and the actin cytoskeleton. Science 279:509-514, 1998
  pubmed

• 11) Heusinger-Ribeiro J, Eberlein M, Wahab NA, et al:Expression ofconnective tissue growth factor in human renal fibroblasts:Regulatory roles of RhoA and cAMP. J Am Soc Nephrol 12:1853-1851, 2001

• 12) Nagatoya K, Moriyama T, Kawada N, et al:Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 61:1684-1695, 2002
  pubmed

• 13) Yoshimura A, Inui K, Nemoto T, et al:Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesngial proliferative nephritis. J Am Soc Nephrol 9:2027-2039, 1998

• 14) Moriyama T, Kawada N, Nagatoya K, et al:Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int 59:2095-103, 2001
  pubmed

• 15) Terada Y, Inoshita S, Nakashima O, et al:Lovastatin inhibits mesangial cell proliferation via p27Kip1. J Am Soc Nephrol 9:2027-2039, 1998

• 16) Eisen R, Ratcliffe DR, Ojakian GK:Modulation of epithelial tubule formation by Rho kinase. Am J Physiol Cell Physiol 286:C857-866, 2004
  pubmed

第11章 診断と治療法の進歩

P.264 掲載の参考文献

• 1) 澤村良勝,田島政晴ほか:腎臓の超音波計測.日超医論文集 89:183-184, 1981

• 2) Miltec D, Fuckar Z, Sustic A, et al:Sonographic measurement of absolute and relative renal length in adults. JClin Ultrasound 26:185, 1998

• 3) Emamian SA, Nielsen MB, Pedersen JF, et al:Sonographic evaluation of renal appearance in 665 adult volunteers. Acta Radiol 34:482, 1993
  pubmed

• 4) Arima M, Takahara S, Ihara H, et al:Predictability of renal allograft prognosis during rejection crisis by ultrasonic Doppler flow technique. Urology 19:389-394, 1982

• 5) Yura T, Takamitsu Y, Yuasa S, et al:Total and split renal function assessed by ultrasound Doppler techniques. Nephron 58:37-41, 1991
  pubmed

• 6) Handa N, Fukunaga R, Etani H, et al:Efficacy of echo-Doppler examination for the evaluation of renovascular disease. Ultrasound in Med&Biol 14:1-5, 1988
  pubmed

• 7) Izumi M, Sugiura T, Nakamura H, et al:Differential diagnosis of prerenal azotemia from acute tubular necrosis and prediction of recovery by Doppler ultrasound. Am J Kidney Dis 35:713-719, 2000
  pubmed

• 8) Sugiura T, Nakamori A, Wada A, et al:Evaluation of tubulointerstitial injury by Doppler ultrasonography in glomerular diseases. Clin Nephrol 61:119-126, 2004
  pubmed

• 9) Claudon M, Plouin PF, Baxter GM, et al:Renal arteries in patients at risk of renal arterial stenosis:multicenter evaluation of the echo-enhancer SH U 508A at color and spectral Doppler US. Levovist Renal Artery Stenosis Study Group. Radiology 214:739-746, 2000

P.268 掲載の参考文献

• 1) 加藤司顯,東原英二:体腔鏡を始める人のために.臨床泌尿器科 57:19-26, 2003

• 2) 東原英二,田中良典,堀江重郎ほか:腹腔鏡下副腎摘除術. 日本泌尿器科学会雑誌 83:395-400, 1992

• 3) 吉井将人,平尾佳彦:マイクロ波手術器の使い方.臨床泌尿器科 55:857-863, 2001

• 4) 加藤司顯,堀江重郎,奴田原紀久雄ほか:マイクロターゼを用いた腹腔鏡下腎部分切除術. Journal of microwave surgery 21:123-127, 2003

• 5) 松田公志:腎動脈遮断による腹腔鏡下腎部分切除術.Urology View 1:50-55, 2003
  Medical*Online

P.273 掲載の参考文献

• 1) Chaussy Ch, Brendel W, Schmiedt E:Extracorporeally induced destruction of kidney stones by shock waves. Lancet 2:1265-1268, 1980

• 2) Masai M, Nakatsu H, Shiseki Y, et al:Treatment of stones on an outpatient basis by extracorponeal shock wave lithotripsy using a EDAP LT-01+. Jpn J Endourol ESWL 4:34-38, 1991

• 3) Mobley TB, Myers DA, Grine WB, et al:Low energy lithotripsy with the lithstar:treatment results with 19, 962renal and ureteral calculi. J Urol 149:1419-1424. 1993

• 4) Hamano S, Nomura H, Kinsui H, et al:Experience with ureteral stones management in 1, 082 patients using semi-rigid ureteroscopes. Urol Int 65:106-111, 2000

• 5) 戸辺豊総,伊藤晴夫:ESWLの最近の動向.垣添忠生監修:泌尿器科-診断と治療の最前線,先端医療技術研究所,東京, p255-264, 2000

• 6) 日本泌尿器科学会,日本Endourology ESWL学会,日本尿路結石症学会編:尿路結石症診療ガイドライン,金原出版,東京,2002

• 7) 金水英俊,野村博之,及川剛宏ほか:Sonolithσを用いた ESWLの臨床経験.泌紀要 45:601-604, 1999

• 8) Gupta PN, Singh VD, Hemal KA, et al:Infundiblopeivic anatomy and clearance of inferior calcial calculi with shock wave lithotripsy. J Urol 163:24-27, 2000

• 9) Christpher S NG, Stevan BS:Contemporary management of cystinurea. J End Urol 13:647-651, 1999

• 10) Alexander L, Markus H, Daniela SL, et al:Urolitiasis in horseshoe kidneys:therapeutic management. Urology 47:182-186, 1996

• 11) Sheir KZ, Madbouly K, Ersobky E, et al:Extracorporeal shock wave lithotripsy in anomalous kidneys:11year experience with two second generation lithotripters. Urology 62:10-15, 2003

• 12) Silver N, Kremer I, Gaston DD, et al:Severe sepsis following extracorporeal shockwave lithotripsy. J Urol 145:1045-1046, 1991

• 13) Myers DA, Mobley TB, McKJenkins J, et al:Pediatric low energy lithotripsy with the Lithostar. J Urol 153:453-457, 1995
  pubmed

• 14) Ather MH, Noor MA, Akhtar S:The effect of intracalyceal distribution on the clearance of renal stones of>20mm in children after extracorporeal lithotripsy. BJU Int 93:827-829, 2004

• 15) 園田孝夫:Endourology, ESWLによる結石治療の評価基準.日泌尿会誌 80:505-506, 1989

• 16) Tiede JM, Lumplin EN, Wass CT, et al:Hemoptysis following extracorporeal shock wave lithotripsy:acase of lithotripsy-induced pulmonary contusion in a pediatric patient. J Clin Anesth 15:530-533, 2003

• 17) Michael AS, Jewett CR, Alexander GL, et al:A randomized controlled trial to assess the incidence of new onset hypertension in patients after shock wave lithotripsy for asymptomatic renal calculi. J Urol 160:1241-1243, 1998

• 18) Rutz-Danielczak A, Pupek-Musialik D, Raszej:a-Wanic B:Effect of extracorporeal shock wave lithotripsy on renal function in patients with kidney stone disease. Nephron 79:162-166, 1998

• 19) 栃木真人:外来ESWL.臨泌 50:289-292, 1996

• 20) 加藤修爾,丹田 均:ESWLその適応拡大の歩み.吉田 修,東間 紘,村井 勝編:泌尿器科疾患の最新医療.先端医療技術研究所,東京,p126-129, 2003

第12章 腎臓疾患治療薬開発の最新情報

P.277 掲載の参考文献

• 1) 大島久二:副腎皮質ステロイド薬の免疫抑制分子作用機構. 炎症と免疫 9:8-15, 2001
  Medical*Online

• 2) Wilckens T, Rijk RD:Glucocorticoids and immune function:Unknown dimensions and new frontiers. Immunol today 18:418-424, 1997

• 3) Yan K, et al:Subcellular localization of glucocorticoid receptor protein in the human glomerulus. Kidney lnt 56:65-73, 1999

• 4) Ratajczak T, Ward BK, Minchin RF:Immunophilin chaperones in steroid receptor signalling. Curr Top Med Chem 3:1348-1357, 2003
  pubmed

• 5) De Bosscher K, et al:Mechanisms of anti-inflammatory action and of immuno-suppression by glucocorticoids:negative interference of activated glucocorticoid recepter with transcription factors. J Neuroimmunol 109:16-22, 2000

• 6) Moldenhauer I, et al:Alteration of structural order of human erythrocyte ghost membrane by glucocorticoids and influence of the glucocorticoid receptor antagonist RU486. In J Tissue React 16:113-119, 1994

• 7) Andreae J, et al:Effect of glucocorticoid therapy on glu-cocorticoid receptors in children with autoimmune diseases. Pediatr Res 49:130-145, 2001

• 8) Sanden S, et al:Glucocorticoid dose dependent downregulation of glucocorticoid receptors in patients with rheumatic diseases. J Rheumatol 27:1265-1270, 2000
  pubmed

• 9) Ou ZL, et al:Effective methylprednisolone dose in experimental crescentic glomerulonephritis. Am J Kidney Diseas 37:411-417, 2001

• 10) Wada T, et al:A new anti-inflammatory compound, FR167653, ameliorates crescentic glomerulonephritis in Wistar-Kyoto rats. J Am Soc Nephrol 11:1534-1541, 2000
  pubmed

• 11) Yokoyama H, Wada T, Furuichi K:Chemokines in renal fibrosis, Razzaque MS, Taguchi T:Renal fibrosis, Contib Nephrol Vol 139, Karger, Basel, p66-89, 2003

• 12) Cattran DC, et al:Management of glomerulonephritis. Kidney Int 55 (suppl 70):S1-62, 1999

• 13) Illei GG, et al:Combination therapy with pulse cyclophos-phamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann lntern Med 135:248-257, 2001

• 14) Haack D, et al:Glucocorticoid receptors in idiopathic nephrotic syndrome. Pediatr Nephrol 13:653-656, 1999
  pubmed

• 15) Yokoyama H, et al:Strategies for treatment of adult nephrotic syndrome by cyclosporin A (cyclosporine). Clin Exp Nephrol 3:S40-47, 1999

• 16) Yoshimoto K, et al:Pathologic findings of initial biopsies reflect the outcomes of membranous nephropathy. Kidney Int 65:148-153, 2004
  pubmed

• 17) Hirano T, et al:Glucocorticoid-resistance in peripheral-blood lymphocytes does not correlate with number of affinity of glucocorticoid-receptors in chronic renal failure. Immunopharmacology 36:57-67, 1997

P.282 掲載の参考文献

• 1) 高橋公太:免疫抑制療法と新規免疫抑制薬.Annual Review腎臓2003,中外医学社,東京, p152-157, 2003

• 2) 大塚一幸:免疫抑制薬.新移植免疫学,中外医学社,東京, p113-139, 2000

• 3) Kaufman DB, Shapiro R, Lucey MR, et al:Immuno suppression:practice and trends. Am J Transplant 4 (supple 9):38-53, 2004

• 4) Sonoda T, Takahara S, Takahashi K, et al:Outcome of 3 years ofimmunosuppression with tacrolimus in more than 1000renal transplant recipients in Japan. Transplantation 75:199-204, 2003

• 5) 田辺一成,東間 紘,高橋公太ほか:わが国における新規腎移植患者に対するBasiliximab (シムレクト) の急性拒絶反応抑制効果および安全性の検討.移植 37:18-31, 2002

• 6) Vincenti F:Adecade of progress in kidney transplantation, Transplantation 77:S52-61, 2004

• 7) 齋藤和英,高橋公太:Basiliximab,腎と透析 55:581-586, 2003

• 8) Kuypers DRJ, Evenepoel P, Maes B, et al:The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal ofsteroids in renal transplant recipients. Clin Transplant 17, 134-141, 2003

• 9) Starzl T, Murase N, Abu-Elmagd K, et al:Tolerogenic immunosuppression for organ transplantation. Lancet 361:1502-1509, 2003
  pubmed

• 10) Calne R, Friend P, Moffatt S, et al:Prope tolerance, perioperative Campath-1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 351, 1701-1702, 1998
  pubmed

• 11) Kirk AD, HaleDA, Mannon RB, et al:Result from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody Alemtuzumab (Campath-1H). Transplantation 76:120-129, 2003
  pubmed

• 12) 千葉健治:スフィンゴシン1リン酸レセプターアゴニストによる循環リンパ球の減少とその応用.臨床免疫 39:220-225, 2003

• 13) Tedesco-Silva H, Mourad G, Kahan BD, et al:FTY720, a novel immunomodulator:efficacy and safety results from the first phase 2A study in de novo renal transplanta-tion. Transplantation 77:1826-1833, 2004

• 14) 市田隆文:免疫抑制剤.医薬ジャーナル40S-1:164-167, 2004

• 15) Vanrenterghem Y, van Hooff JP, Klinger M, et al:The effects of FK778 in combination with tacrolimus and ste-roids:aphase n multicenter study in renal transplant patients. Transplantation 78:9-14, 2004

P.285 掲載の参考文献

• 1) 中山謙二,伊藤貞嘉:高血圧性腎疾患の治療とフォローアップ.現代医療 36:401-405, 2003

• 2) Guidelines Committee:2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension 21:1011-1053, 2003

• 3) Katayama S, Kittaka R, Isogai S, et al:Effect of captpril or imidapril on the progression of diabetic nephropathy in Japanese with type l diabetes mellitus. Diabetes Res Clin Pract 55:113-121, 2002

• 4) Morgensen CE, Neldom S, Tikkanen I:Randomised controlled trial of dual blockade of rennin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes. BMJ 321:1440-1444, 2000

• 5) Nakao N, Yoshimura A, Morita H, et al:Combination treatment of angiotensin-ll receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE):arandomised controlled trial. Lancet 11:117-124, 2003

• 6) Rossing K, Jacobsen P, Pietraszek L, et al:Renoprotective effects of adding angiotensin H receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy:arandomized double-blind crossover trial. Diabetes Care 26:2268-2274, 2003

• 7) Sato A, Hayashi K, Naruse M, et al:Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41:64-68, 2003
  pubmed

• 8) Epstein M:Aldosterone receptor blockade and the role of eplerenone:evolving perspectives. Nephrol Dial Transplant 18:1984-1892, 2003
  pubmed

• 9) Mogensen CE, Cooper ME:Diabetic renal disease:from recent studies to improved clinical practice. Diabet Med 21:4-17, 2004
  pubmed

• 10) Stanton A, Jensen C, Nussberger J, et al:Blood pressure lowering in essential hypertension with a oral renin inhibitor, aliskiren. Hypertension 42:1137-1143, 2003
  pubmed

• 11) Cao Z, Burrell LM, Tikkanen I, et al:Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney lnt 60:715-721, 2001

• 12) Cases A:Omapatrilat:clinical pharmacology. Drugs Today ( Barc) 36:817-828, 2000
  pubmed

• 13) Taal MW, Nenov VD, Wong W, et al:Vasopeptidase inhibition affords greater renoprotection than angiotensinconverting enzyme inhibition alone. J Am Soc Nephrol 12:2051-2059, 2001
  pubmed

• 14) Regamey F, Maillard M, Nussberger J, et al:Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men. Hypertension 40:266-272, 2002
  pubmed

• 15) Kanda T, Wakino S, Hayashi K, et al:Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int 64:2009-2019, 2003
  pubmed

P.291 掲載の参考文献

• 1) KAoyagi, et al:Role of active oxygen on methylguanidine synthesis in isolated rat hepato cytes. Kidney International 23 (Suppl 22):S229-233, 1987

• 2) Aoyagi K, Nagase S, Tomida C, et al:Synthesis of Guanidinosuccinate from Argininosuccinate and Reactive oxygen in vitro. Enzyme&Protein 49:199-204, 1996
  pubmed

• 2) Aoyagi K, Ohba S, Narit M, et al:Regulation of biosynthesis of guanidinosuccinic acid in isolated rat hepatocytes and in vivo. Kidney Int 24 (Supple 16):S224-228, 1983

• 3) 青柳一正,成田光陽:各種疾患のフリーラジカルと漢方薬腎疾患.奥田拓男,吉川俊一編:フリーラジカルと和漢薬, 国際遺書出版,東京,p147-158, 1990

• 4) Suh YA, Arnoid RS, Lassegue B, et al:Cell transformation by the superoxide-generating oxidase MOx1. Nature 401:79-82, 1999

• 5) Grewal JS, et al:Serotonin 5-HT2A receptor induces TGF-betal expression in mesangial cells via ERK:proliferative and fibrotic signals. Am J Physiol 276:F922-930, 1999

• 6) Jaimes EA, et al:Angiotensin H induces superoxide an ion production by mesangial cells. Kidney lnt 54:775-784, 1998

• 7) Mazifari A, et al:Arachidonic acid metabolites mediate angiotensin n-induced NADHINADPH oxidase activity and hypertrophy in vascular smooth muscle cells. Antioxidants & Redox Signaling 1:167-179, 1999

• 8) Aoyagi K, et al:Chapter 16, Products of creatinine withhydroxyl radical as a useful marker of oxidative stress invivo. in Methods in Molecular Biology, Vol 108:Free Radical and Antioxidant Protocols (D Armstrong), The Humana Press Inc, USA, p157-164, 1998

• 9) Aoyagi K, et al:The role of protein kinase C in the increased generation in isolated rat hepatocytes of the hydroxyl radical by puromycin aminonucleoside. Free Radical Reseach (in press)

• 10) Aoyagi K, Narita M:Mechanism of abnormal active oxygen generation in tissue cells by puromycin aminonucleoside. Acta Medica Biologica 39 (Suppl):53-62. 1991

• 11) 青柳一正ほか:STZラットにおけるハイドロキシルラジカル産生増加とその経時変化:クレアトールとメチルグアニジンの尿中排泄量による検討.伊藤克己,玄番宗一編:腎とフリーラジカル5,東京医学社,p92-93, 2000

• 12) Aoyagi K, Kuzure Y, Shahrzad S, et al:Inhibition by heparin of protein kinase C activation and hydroxyl radical generation in puromycin aminonucleoside treated isolated rat hepatocytes. Mol Cell Biochem 244:3-9, 2003
  pubmed

• 13) Vinik A, Tesfaye S, Zhang D, et al:LY333531 treatment improves diabetic neuropathy (DPN) with symptoms. Presented at 62nd Scientific Sessions of American Diabetes Association, San Francisco, 2002 (abstract#321)

• 14) Aoyagi K:Inhibition of arginine synthesis by urea:a mechanism for arginine deficiency in renal failure which leads to increased hydroxyl radical generation. Mol Cell Biochem 244:11-15, 2003
  pubmed

• 15) Miyazaki M, Aoyagi K, Ohba S, et al:The Effect of Lactulose on the Metabolism of Guanidino compounds in Chronic Renal Failure. Guanidines, Plenum publishing corporation, New York, p343-352, 1985

第13章 各種製品の臨床評価

P.294 掲載の参考文献

• 1) Luqmani RA, Bacon PA, Moots RJ, et al:Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87:671-678, 1994
  pubmed

• 2) Guillevin L, Lhote F:Treatment of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 41:2100-2105, 1998
  pubmed

• 3) Kashiwagi N, Hirata I, Kasukawa R:A role for granulocyte and monocte apheresis in the treatement of rheumatoid arthritis. Ther Apheresis 2:134-141, 1998

• 4) 柏木伸仁,朝倉昭子郎,井出達夫ほか:家兎の感作関節炎に対する顆粒球体外吸着療法の効果.炎症 14:313-322, 1994
  Medical*Online

• 5) 柏木伸仁,橘 武彦,足立正一:顆粒球除去療法の開発と臨床応用.炎症と免疫 7:371-377, 1999
  Medical*Online

P.299 掲載の参考文献

• 1) Shire Pharmaceutical Group plc:Press release, March 24, 2004

• 2) Shire Pharmaceutical Group plc:Press release, October 27, 2004

• 3) Emmett M:A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int 66 (Suppl 90):S25-32, 2004

• 4) National Kidney Foundation:K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42 (4) (Suppl 3):S62-84, 2003

• 5) Date T, Shigematsu T, Kawashita Y, et al:Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients. Nephrol Dial Transplant 18 (Suppl 3):iii90-93, 2003

• 6) Locatelli F, D:Amico M, Pontoriero G:Lanthanum Carbonate. IDrugs 6 (7):688-695, 2003
  pubmed

• 7) Damment SJP, Webster 1:Nephrol Dial Transplant 18:(Suppl 4):683, 2003

• 8) Damment SJP, Webster 1:Poster presented at the 36th Annual Meeting of the American Society of Nephrology, San Diego, 14-17, November, 2003

• 9) Pennick M, Damment SJP, Gill M:Poster presented at the 36th Annual Meeting of the American Society of Nephrology, San Diego, 14-17, November, 2003

• 10) Stewart AJ, Fiddler G, Webster I:Poster presented at the 9th Asian Pacific Congress of Nephrology, Pattaya, 16-20, February, 2003

• 11) Finn WF, Joy MS:Poster presented at the 9th Asian Pacific Congress of Nephrology, Pattaya, 16-20, February, 2003

• 12) Fiddler G, Taeubel J, Webster I, et al:Poster presented at the 40th ERA-EDTA World Congress of Nephrology, Berlin, 8-12, June, 2003

• 13) Joy MS, Finn WF (the LAM-302 Study Group):Am J Kidney Dis 42 (1):96-107, 2003

• 14) Hutchison AJ:Poster presented at the Annual Meeting of the American Society of Nephrology, Philadelphia, 1-4, November, 2002

• 15) Hutchison A, AI F Baaj (on behalf of the International Lanthanum Carbonate Study group):Poster presented at the National Kidney Foundation Clinical Meeting, Dallas, 2-6, April, 2003

• 16) Finn WF, Joy MS, Webster I:Poster presented at the 36th Annual Meeting of the American Society of Nephrology, San Diego, 14-17, November, 2003

• 17) D:Haese PC, Spasovski GB, Sikole A, et al:Kidney Int 63 (Suppl 85):S73-78, 2003

技術資料編

P.305 掲載の参考文献

• 1) 伊藤隆司,谷口寿章共編:プロテオミクス,ポストシークエンスのゲノム科学第3巻,中山書店, 東京,p12-23, 2000

• 2) Mitchell P:In the pursuit of industrial proteomics. Nat Biotechnol 21 (3):233-237, 2003
  pubmed

• 3) Perkins DN, et al:Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20 (18):3551-3567, 1999
  pubmed

• 4) Gygi SP, et al:Quantitative analysis of complex protein mixture using isotope-coded affinity tags. Nat Biotechnol 17:994, 1999
  pubmed

• 5) Hansen KC, et al:Mass spectrometric analysis of protein mixtures at low levels using cleavable 13C-isotope coded affinity tag and multidimensional chromatography. Mol Cell Prote mics 2 (5):299, 2003

• 6) Emili AQ, cagney G:Large-scale functional analysis using Peptide or protein arrays. Nat Biotechnol 18:393, 2000
  pubmed

• 7) Caprioli RM, Farmer TB, Gile J:Molecular imaging of biological samples:localization of peptides and proteins using MALDI-TOF MS. Anal Chem 69:4751, 1997
  pubmed

P.307 掲載の参考文献

• 1) Sanaka T, et al:Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure. NEPHRON 91:64-73, 2002
  pubmed

• 2) 佐中 孜ほか:競合EHSA法による血漿ペントシジンの測定法の確立と慢性腎不全患者における血漿ペントシジン濃度.腎と透析 47:867-872, 1999

• 3) 佐中 孜ほか:慢性腎不全の早期診断マーカーとしてのペントシジン測定の有用性.腎と透析 56:777-783, 2004

• 4) 加藤陽二ほか:Quantification of AGE and oxidative Stress Biomarkers in Human Urine. 第 8回国際メイラード反応研究会, 2004

P.311 掲載の参考文献

• 1) 谷叙孝:デキストラン硫酸を使った吸着材の原理と性能.日アフェレシス会誌 19:86-91, 2000

• 2) Moorhead JF, et al:Lipids and progressive glomerulosclerosis. Lancet ii:1309-1311, 1982

• 3) Diamond JR, et al:Analogous pathobiologic mechanisms in glomerulosclerosis and athero-sclerosis. Kidney Int 39:S29-34, 1991

• 4) 酒井聡一ほか:血漿交換療法の現況と展望.腎と透析 22:795-803, 1987

• 5) 酒井聡一ほか:難治性ネフローゼ症候群に対する LDL吸着療法の臨床効果-多施設共同研究成績-.腎と透析 33:321-328, 1992

• 6) Muso E, et al:Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 89:408-415, 2001
  pubmed

• 7) Hattori M, et al:Acombined low-density lipo-protein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 42:1121-1130, 2003

• 8) 横山啓太郎,酒井聡一:難治性ネフローゼ症候群の治療-アフェレーシス療法.腎と透析 40:115-120, 1996

• 9) Muso E, et al:Does LDL-apheresis in steroid resitant nephrotic syndrome affect prognosis? Nephrol Dial Transplant 9:257-264, 1994

• 10) 吉澤亜人ほか:ステロイド抵抗性ネフローゼ症候群に対するLDL-アフェレーシスの有用性に関する検討.日腎会誌 45:25-31, 2003

• 11) 内田俊也ほか:LDL吸着療法はFSGSに有効か. 腎と透析 40:607-611, 1996

• 12) Sakurai M, et al:Rapid normalization of interleukin-8 production after low-density lipo-protein apheresis in steroid-resistant nephrotic syndrome. Kidney lnt Suppl 71:S210-212, 1999

• 13) 近本裕子ほか:難治性原発性FSGS例における LDL吸着療法によるステロイド感受性の改善に関する検討.Ther Res 21:2638-2639, 2000
  Medical*Online

• 14) Lieberman KV, et al:Aramdomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 7:56-63, 1996

• 15) 岡田知也ほか:LDL吸着療法を契機にシクロスポリンが奏効したステロイド抵抗性微小変化型ネフローゼ症候群の一例.日腎会誌 38:46-51, 1996

• 16) Hirano T, et al:Implication of cholesterol in cyclosporine pharmacodynamics in minimal change nephrotic syndrome. Clin Pharmacol Ther 74:581-590, 2003
  pubmed

• 17) 武曾恵理:難治性ネフローゼ症候群へのLDLアフェレシス療法-症例のまとめと新しい方向性について-.Ther Res 24:1237-1239, 2003
  Medical*Online

• 18) Akhlaghi F, et al:Distribution of cyclosporine in organ transplant recipients. Clin Pharmacokinet 41:615-637, 2002
  pubmed

• 19) 斉藤喬雄:難治性ネフローゼ症候群.内科 94:91-95, 2004

• 20) Kojima S, et al:Changes in coagulation factors by passage through a dextran sulfate cellulose column during low-density lipoprotein apheresis. Int J Artif Organs 15:185-190, 1992
  pubmed

• 21) Hattori M, et al:Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis. Pediatr Nephrol 7:196-198, 1993
  pubmed

• 22) 河内 裕,清水不二雄:ネフローゼ症候群の成因-タンパク尿発症機序についての最近の知見.内科 94:5-12, 2004

• 23) 服部元史ほか:尿沈渣ポドカリキシン陽性細胞からみた高脂血症による糸球体上皮細胞障害.腎と脂質研究会講演記録集 9:10-13, 1996

• 24) 堺 秀人ほか:難治性ネフローゼ症候群 (成人例) の診療指針-平成13年度までの調査研究より-.日腎会誌 44:751-761, 2002

• 25) 池田裕史ほか:LDL Apheresisが有効であった微小変化型ネフローゼ症候群の3例.Ther Res 24:1293-1296, 2003

• 26) Stenvinkel P, et al:LDI.-apheresis in patients with nephrotic syndrome:effects on serum albumin and urinary albumin excretion. Eur J Clin Invest 30:866-870, 2000

• 27) 柴田哲雄ほか:急性腎不全を合併しLDLアフェレーシスにて寛解したIgA腎症によるネフローゼ症候群の1例.透析会誌 27:233-236, 1994

• 28) 中尾俊之ほか:糖尿病性腎症に対するLDLアフェレシス.日アフェレシス会誌 17:85-90, 1998

• 29) 田上哲夫ほか:糖尿病性腎症に対する長期LDL 吸着療法の試み.Ther Res 24:1290-1292, 2003
  Medical*Online

• 30) Kobayashi S, et al:LDL-apheresis for diabetic nephropathy:apossible new tool. Nephron 79:505-506, 1998

• 31) Iwahori T, Yoshida M:Low-density lipoprotein apheresis can improve type AA systemic amyloidosis. Nephron 86:248-250, 2000
  pubmed

• 32) 渋谷正樹ほか:難治性ネフローゼ症候群を呈し, LDL吸着療法およびフェノフィブラートの併用が有効であったループス腎炎の1例.Ther Res 23:1364-1366, 2002
  Medical*Online

• 33) 斉藤喬雄ほか:リポ蛋白糸球体症 (LPG) におけるLDLアフェレーシス.透析会誌 37 (suppl 1):618, 1999

• 34) Nakamura T, et al:Low-density lipoprotein apheresis in a patient with arteriosclerosis obliterans and light chain deposition disease. Clin Nephrol 61:429-433, 2004

• 35) Yanagisawa T, et al:Massive proteinuria after renal transplantation treated with LDL-apheresis. Transplant Proc 28:1482-1483, 1996
  pubmed

• 36) Daimon S, et al:LDL apheresis followed by corticosteroid therapy as a possible treatment of cholesterol crystal embolism. Clin Exp Nephrol 4:352-355, 2000

• 37) Tamura K, et al:Acute renal failure due to cholesterol crystal embolism treated with LDL apheresis followed by corticosteroid and candesartan. Clin Exp Nephrol 7:67-71, 2003
  pubmed

• 38) 大石徹也ほか:免疫吸着療法を施行したループス腎炎の2例.腎と透析 36:349-354, 1994

• 39) Kutsuki H, et al:Therapeutic selective adsorption of anti-DNA antibody using dextran sulfate cellulose (Selesorb) for the treatment of systemic lupus erythematosus. Ther Apher 2:18-24, 1998
  pubmed

• 40) Mistry-Burchardi N, et al:Apheresis in lupus nephritis. Ther Apher 5:161-170, 2001
  pubmed

P.315 掲載の参考文献

• 1) Desnick RJ, Ioannou YA, Eng CM:α-Galacto-sidase A deficiency:Fabry diseae.:Scriver CR, Beaudet AL, Sly WS, et al editors:The Metabolic and Molecular Bases of Inherited Disease. 8th ed. McGraw-Hill, New York, p3733-3774, 2001

• 2) Meikle PJ, Hopwood JJ, Clague AE, et al:Prevalence of Lysosomal Storage Disorders. JAMA 281 (3):249-254, 1999
  pubmed

• 3) Anderson W:A case of "Angio-keratoma". Br J Dermatol 10:113-117, 1898

• 4) Fabry J:Ein Beitrag Zur Kenntniss der Purpura haemorragica nodularis (Purpura papulosa hemorrhagica Hebrae). Arch Dermatol Syph 43:187-200, 1898

• 5) Sweeley CC, Klionsly B:Fabry's disease. Classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 238:3148, 1963

• 6) Kint JA:Fabry's disease. α-Galactosidase deficiency. Science 167:1268, 1970

• 7) Mapes CA, Desnick RJ, Krivit W:Enzyme replacement in Fabry's disease, an inborn error of metabolism. Science 169:987, 1970
  pubmed

• 8) Brady RO, Tallman JF, Johnson WG, et al:Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease. N Engl J Med 289:9, 1973
  pubmed

• 9) Desnick RJ, Dean KJ, Grabowski G, et al:Enzyme therapy in Fabry disease:Differential in vivo plasma clearance metabolic effectiveness of plasma and splenic α-galacotsidase isozymes. Proc Natl Acad Sci USA 76:5326, 1979

• 10) Kornreich R, Desnick RJ, Bishop DF:Nucleotide sequence of human α-galactosidase A gene. Nucleic Acids Res 17:3301, 1989

• 11) 桜庭 均:XII. 治療法-2. ファブリー病の酵素補充療法.Annual Review 2004腎臓,231-236, 2004

• 12) Lee K, Jin X, Zhang K, Edmunds T, et al:A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid strorage disorder Fabry disease. Glycobiology 13 (4):305-313, 2003

• 13) Eng CM, Banikazemi M, Desnick RJ, et al:A Phase 1/2 Clinical Trial of Enzyme Replacement in Fabry Disease:Pharmacokinetic, Substrate Clearance, and Safety Studies. Am J Hum Genet 68:711-722, 2001
  pubmed

• 14) Eng CM, Guffon N, Desnick RJ, et al:Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease. N Engl J Med 345 (1):9-16, 2001

• 15) Wilcox WR, Banikazemi M, Guffon N, et al:Long-term Safety and Efficacy of Enzyme Replacement Therapy for Fabry Disease. Am J Hum Genet 75:65-74, 2004
  pubmed

• 16) 衛藤義勝,大橋十也,宇都宮保則ほか:日本人ファブリー病患者における酵素補充療法:第II相オープン試験の結果.小児科診療 66 (8):1435-1444, 2003

• 17) Schoenmakere GD, Chauveau D, Grunfeld JP:Enzyme replacement therapy in Anderson-Fabry's disease:beneficial clinical effect on vital organ function. Nephrol Dial Transplant 18:33-35, 2003

• 18) Siamopoulos KC:Fabry's disease:Kidney involvement and enzyme replacement therapy. Kideny Int 65:744-753, 2004

• 19) Weidemann F, Breunig F, Beer M, et al:Improvement of Cardiac Function During Enzyme Replacement Therapy in Patients With Fabry Disease. A Prospective Strain Rate Imaging Study. Circulation 108:1299-1301, 2003
  pubmed

• 20) Spinelli L, Pisani A, Sabbatini M, et al:Enzyme replacement therapy with aglasidase βimproves cardiac involvement in Fabry's disease. Clin Genet 66:158-165, 2004

• 21) Hilz MJ, Brys M, Marthol H, et al:Enzyme replacement therapy improves function of C-, A δ-, and A β-nerve fibers in Fabry neuropathy. Neurology 62:1066-1072, 2004

• 22) Guffon N, Fouilhoux A:Cinical benefit in Fabry patients given enzyme replacement therapy-A case series. J lnherit Metab Dis 27:221-227, 2004

P.320 掲載の参考文献

• 1) 厚生省厚生科学研究シルバーサイエンス研究高齢者に投与最適な新規製剤及び新規包剤容器の作成研究, 1988

• 2) 安藤正樹,幸崎敏之,樋口文男ほか:ポリスチレンスルホン酸カルシウムを含有するゼリー状製剤に関する検討.薬剤学 60:261-270, 2000
  Medical*Online

• 3) 前田憲志,山崎親雄,天野 泉ほか:慢性腎不全に伴う高カリウム血症に対するSK-189 (アーガメイトゼリー) の臨床的検討.腎と透析 49:137-152, 2000

• 4) 丸山高史,久野 勉,高橋佳子ほか:維持透析患者に対する陽イオン交換樹脂製剤のアーガメイトゼリーと散剤のクロスオーバー試験.臨床透析 19:1643-1649, 2003

• 5) 高嶋孝次郎,水野賀夫,有田光一ほか:血液透析患者におけるアーガメイトゼリーおよびカリメートの比較検討.医療薬学 30:584-587, 2004

P.324 掲載の参考文献

• 1) Ruilope LM, et al:Losartan and Other Angiotensin H Antagonists for Nephropathy in Type 2 Diabetes Mellitus:A Review of the Clinical Trial Evidence. Clin Ther 25 (12):3044-3064, 2003

• 2) Andersen S, et al:Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 17 (8):1413-1418, 2002
  pubmed

• 3) Lewis E J, et al:The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. N Engl J Med 329:1456-1462, 1993
  pubmed

• 4) Brenner B M, et al:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
  pubmed

• 5) Chan J C N, et al:Renin Angiotensin Aldoster-one System Blockade and Renal Disease in Patients With Type 2 Diabetes-An Asian perspective from the RENAAL studey. Diabetes Care 27:874-879, 20004

P.328 掲載の参考文献

• 1) Ishikawa H:Mizoribine and Mycophenolate Mofetil. Curr Med Chemi 6:575, 1999

• 2) Shibazaki T, Sakai O, et al:Mizoribine Reduces Urinary Protein Excretion in Rats Given Puromycin Amino-nucleoside. Am J Nephrol 16:167, 1996

• 3) 佐藤則博,白岩和巳:単クローン抗体5-1-6腎炎ラットにおけるミゾリビンの尿中蛋白排泄抑制効果.細胞 33 (1):28, 2001

• 4) Sato N, Shiraiwa K, Kobayashi Y, et al:Mizoribine Ameriorats the Tubulointerstitial Fibrosis of Obstructive Nephropathy. Nephron 89:177, 2001
  pubmed

• 5) 越川昭三ほか:免疫抑制薬ミゾリビン (HE-69) のステロイド抵抗性ネフローゼ症候群に対する臨床評価-プラセボを対照とした二重盲検比較試験-.腎と透析 34 (4):631, 1993

• 6) Shibazaki T, Sakai O, et al:A randomized open-label comparative study of conventional therapy verus mizoribine on lay therapy inpatients with steroid-resistant nephrotic syndrome (post marketing surrey). Clin Exp Nephrol 8:117, 2004

• 7) 湯村和子ほか:ループス腎炎における免疫抑制剤ミゾリビンの血中濃度の評価.腎と透析 47 (5):705, 1999

• 8) Tanaka H, et al:Mizoribine oral pulse therapy for a patient with severe lupus nephritis. Pediatrics International 45:488, 2003
  pubmed

P.331 掲載の参考文献

• 1) Chatenoud L, et al:Antigenic modulation a major mechanism of antibody action, Immunol Today 5:20-25, 1984

• 2) 太田和夫ほか:腎移植後の急性拒絶反応に対する muromonab CD3の治療効果.腎と透析 27:143-156, 1989

• 3) 伊藤克己ほか:小児腎移植後の急性拒絶反応に対するmuromonab CD3の治療効果.小児科臨床 42:1551-1560, 1989
  Medical*Online

P.337 掲載の参考文献

• 1) Twardowski ZJ, et al:0smotic agent and ultrafiltration in peritoneal dialysis. Nephron 42:93-101, 1986
  pubmed

• 2) Mujais S:Ultrafiltration failure. In Gokal R, Khanna R, Krediet R, Nolph K, editors:Text-book of Peritoneal Dialysis, 2nd ed, p499-513, 2000

• 3) Jolly S, et al:Excessive weight gain during peritoneal dialysis. Int Artif Organs 24:197-202, 2001
  pubmed

• 4) Boeschoten EW, et al:Changes in weight and lipid concentration during CAPD treatment. Perit Dial Int 8:19-24, 1988

• 5) Lameire N, et al:Effects of longterm CAPD on carbohydrate and lipid metabolism. Clin Nephrol 30:S53-58, 1988
  pubmed

• 6) Liberek T, et al:Peritoneal Dialysis fluid inhibition of phagocyte function:effects of osmolarity and glucose concentration. J Am Soc Nephrol 3:1508-1515, 1993
  pubmed

• 7) Nakayama M, et al:Immuno histochemical detection of advanced glycosylation end-products on the peritoneum and its possible pathophysiological role in CAPD. Kidney lnt 51:182-186, 1997

• 8) Mistry CD, et al:Icodextrin in peritoneal dialysis:early development and clinical use. Perit Diallnt 14 (suppl 2):S13-21, 1994

• 9) 太田和夫ほか:本邦におけるイコデキストリン透析液の臨床成績:ブドウ糖透析液を対照薬とした二重盲検比較試験の結果.腎と透析 55:211-219, 2003

• 10) Ota K. et al:Peritoneal Ultrafiltration and Serum lcodextrin Concentration During Dialysis with 7.5% Icodextrin Solution in Japanese Patients. Perit Dial Int 23:356-361, 2003
  pubmed

• 11) Ates K, et al:Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 60:767-777, 2001
  pubmed

• 12) Nakayama M, et al:Multicenter Survey on Hydration Status and Control of Bllod Pressure in Japanese CAPD patients. Perit Dial Int 22:411-441, 2002

P.340 掲載の参考文献

• 1) Kreutmann HT, et al:Complete Amino Acid Sequence of Human Parathyroid Hormone. Bio-chemistry 17:5723-5729, 1978

• 2) Cohn DV, MacGregor RR:The Biosynthesis, Intracellular Processing, and Secretion of Parathormone. Endocr Rev 2:1-26, 1981
  pubmed

• 3) Lepage R, et al:A non (1-84) circulating para-thyroid hormone (PTH) ineteferes with intact PTH commercial assay measurements in uremic samples. Clin Chem 44:805-809, 1998

• 4) Savoca R, et al:An automated 'bio-intact' PTH assay:a step towards standardization and improved correlation with parathyroid function in renal disease. Clin Chem Acta 343:167-171, 2004

• 5) Inaba M, et al:Technical and Clinical Characterization of the Bio-PTH (1-84) Immunochemi-luminometric Assay and Comparison with a Second-Generation Assay for Parathyroid Hormone. Clin Chem 50 (2):385-390, 2004

• 6) Goodman W, et al:Specific measurement of PTH (1-84) in Various Forms of Renal Osteodystrophy (ROD) Assessed by Bone Histomorphometry. J Am Soc Nephrol 14:SU-PO 706, 2003

P.347 掲載の参考文献

• 1) 佐々木正富:ダイアライザーに用いられる膜の特徴:再生セルロース (血液透析スタッフのためのハイパフォーマンスメンブレン).東京医学社, 東京,p11-17,1990

• 2) 佐々木正富:一般的な再生セルロース膜とビタミンE改質セルロース (新しいハイパフォーマンスメンブレン),東京医学社,東京,p13-27,1998

• 3) Sasaki M, Takahashi A, Ito H, et al:Developmemt of Blood-compatible Cellulose Membranes for Hemodialysis:Cellulose structure and functional aspect:457-472, 1989

• 4) 星野政陽,佐々木正富,北村 真ほか:濾液再生方法による新しい血液浄化システムの開発.人工臓器 26 (1):147-152, 1997

• 5) 鈴木 大,飛田美穂,佐々木正富ほか:濾液再生方法による血液浄化システムの開発及び臨床評価.人工臓器 26 (1):153-156, 1997

• 6) 森田浩智,佐々木正富,斉藤 明:再生セルロースハイパーフォーマンスメンブランの大孔径化. 人工臓器 18 (3):1137-1140, 1989

• 7) 猿橋 誠,細矢範行,佐々木正富:再生セルロースハイパーフォーマンスメンブランの膜物性評価.人工臓器 24 (3):1015-1020, 1992

• 8) 森田浩智,谷利樹,佐々木正富:ノンスライスヘッターによる抗血栓性に優れたダイアライザーの開発.人工臓器 21 (3):1011-1014, 1992

• 9) 細矢範行,佐々木正富,竹沢真吾ほか:in vitro 実験によるplug透析器とpost dilution HDFの性能評価.医工学治療 10 (1):59-61, 1996

• 10) 細矢範行,佐々木正富,竹沢真吾:大量液置換可能な透析器の性能評価 (Plug透析器).人工臓器 25 (1):107-112, 1996

• 11) 細矢範行,佐々木正富,竹沢真吾:大量液置換可能な透析器の開発.腎と透析 (別冊):94-96, 1995

• 12) Satoh M, Nagake Y, Makino H, et al:Oxidative stress is reduced by the long-term use of Vitamin E-Coated Dialysis filters. Kidney International 59:1943-1950, 2001

• 13) Sanaka T:Active oxygen hypothesis. Jpn J Artif Organs 24 (3):283-287, 1991

• 14) Tarhg D, Sung Y, Wei Y, et al:Effect of Vitamin E-bonded membrane on the 8-hydroxy 2-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney International 58:790-799, 2000

• 15) Bonnefont-Rousselot D, et al:Blood oxidative stress and lipoprotein oxidizability in haemodialysis patients:effect of the useof a vitamin E-coated dialysis membrane. Nephrology Dialysis Transplantation 15:2020-2028, 2000

• 16) Tanimu D, Giles C, Pagayon Ym, et al:The Effect of Vitamin E-Modified Dialysers on Acute Intra-dialytic Symptoms:a Comparative Crossover Study. Saudi Journal of Kidney Diseases and Transplantation 11 (4):559-562, 2000

• 17) Shimazu T, et al:Effect of Vitamin E-Modified Regenerative Cellulose Membrane on Neutrophil Superoxide Anion Radical Production and Lipid Peroxidation. Vitamin E-Bonded Membrane. A Further Step in Dialysis Optimization. Contrib Nephrol. Basel, Karger 127:251-260, 1999

• 18) Galli F, Canestrari F, Buoncristiani U, et al:Bioreactivity and biocompatibility of a vitamin E Modified multilayer hemodialysis filter. Kidney International 54, 580-589, 1998
  pubmed

• 19) Sasaki M. Saruhashi M. Hosoya N. Vitamin E Modified Cellulose Membrane. Artif Organs 24 (10):779-789, 2000
  pubmed

• 20) 猿橋 誠,森田浩智,佐々木正富ほか:表面改質セルロース膜の開発とその生体適合性評価.人工臓器 21 (3):1025-1030, 1992

• 21) Sasaki M, Saruhashi M, Hosoya N:Developmemt of Vitamin E Modified Cellulose Membrane. Contrib Nephrol. Basel, Karger, 127:49-70, 1999

• 22) 江本秀斗,佐々木正富:ビタミンE固定化ダイアライザーの脂質:に及ぼす影響 (H).Vitamembrane:16-18, 2001

• 23) Sasaki M, Hosoya N, Saruhashi M, et al:Vitamin E Modified Cellulose Membrane. Membrane 19 (6):400-410, 1994

• 24) Sasaki M, Vitamin E, Modified Cellulose Membrane. Membrane 20 (3):239-241, 1995

• 25) 猿橋 誠,渡辺秀樹,佐々木正富:ビタミンE改質セルロース膜の生体適合性評価.人工臓器 24 (3):631-636, 1995

• 26) 猿橋 誠,佐々木正富ほか:ビタミンE固定化ダイアライザーCL-EEの抗酸化作用に関する基礎検討.人工臓器 29 (1):161-165, 2000

• 27) 佐々木正富,猿橋誠:ビタミンE固定化ダイアライザー,CL-EEの抗酸化作用に関する基礎的検討,Vitamembrane:22-29, 2001

• 28) Takagi T, Momoi T, Ono M, et al:Biocompatibility of modified regenerated cellose membrane (CL-E). Kidney Dial High perform mem:9436:128-131, 1994

• 29) Ono M, Takagi T, Saito A:Clinical evaluation of dialyzer CL-12E. Jpn J Clin Dial 10 (10):1585-1591, 1994

• 30) Shimazu T, Oowada S, Ishida M, et al:Effects of a vitamin E-modified dialysis membrane on neutrophil superoxide anion radical production. Kidney International 59 (Suppl 78):137-143, 2001

• 31) Miroslav M, Katarina D, 01iver R, et al:A modified dialyzer with vitamin E and antioxidant defense parameters. Kidney lnternational 59 (Suppl 78):144-147, 2001

• 32) Galli F, Varga Z, Buoncristiani, et al:U. Vita-min E, lipid profile, and peroxidation in hemo-dialysis patients. Kidney International 59 (Suppl 78):148-154, 2001

• 33) Huraib S, Giles C, Pagayon V, et al:Effect of Vitamin-E-Modified Dialysers on Dialyser Clotting, Erythropoietin and Heparin Dosage:A Comparative Crossover Study. American Journal of Nephrology 20:364-368, 2000
  pubmed

• 34) Omata M, Sanaka T, Nihei N, et al:Reduction of Neutrophil Activation by Vitamin E Modiied Dialyzer Membranes. Nephron 85:221-231, 2000

• 35) Inal M, Kanbak G, Sunal E, et al:Antioxidant Status and Lipid Peroxidation In Hemodialysis Patients Undergoing Erythropoietin and Erythropoietin-Vitamin E Combined Therapy. Free Rad Res 31:211-216, 1999

• 36) Taccone-Gallucci M, et al:Chronic Haemolysis and Erythrocyte Survival in Haemodialysis Patients Treated with Vitamin E-Modified Dialysis Filters. Vitamin E-Bonded Membrane. A Further Step in Dialysis Optimization. Contrib Nephrol. Basel, Karger 127:44-48, 1999

• 37) Calzavara P, et al:Morphologic Evaluation of Red Blood Cells Using Vitamin E-Modified Dialysis Filters. Vitamin E-Bonded Membrane. A Further Step in Dialysis Optimization. Contrib Nephrol. Basel, Karger 127:172-176, 1999

• 38) Usberti M, et al:Increased Red Blood Cell Survival Reduces the Need of Erythropoietin in Hemodialyzed Patients Treated with Exogenous Glutathione and Vitamin E-Modified Membrane. Vitamin E-Bonded Membrane. A Further Step in Dialysis Optimization. Contrib Nephrol. Basel, Karger 127:208-214, 1999

• 39) 0detti P, et al:Effect of a New Vitamin E-Coated Membrane on Glycoxidation during Hemodialysis. Vitamin E-Bonded Membrane. A Further Step in Dialysis Optimization. Contrib Nephrol. Basel, Karger 127:192-199, 1999

• 40) Morena M, et al:Dose Vitamin E Bound on Dialysis Membrane Improve the LDL Susceptibility to Oxidation?Lessons from an in vitro Model. Vitamin E-Bonded Membrane. A Further Step in Dialysis Optimization. Contrib Nephrol. Basel, Karger 127:251-260, 1999

• 41) Mine M, Yukawa S, Yamada Y, et al:Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney International 56 (Suppl 71):S126-129, 1999

• 42) Francesco Galli, et al:Bioreactivity and biocompatibility of a vitamin E-modified multilayer hemodialysis filter. Kidney International 54:580-589, 1998

• 43) Noiri E, Nakao A, Fujita T, et al:Serum protein acrolein adducts:Utility in detecting oxidant stress in hemodialysis patients and reversal using Vitamin E-bonded Hemodialyzer. Free Radical Biology&Medicine 33 (12):1651-1656, 2002
  pubmed

P.354 掲載の参考文献

• 1) Block GA, Port FK:Re-evaluation of risks associated with hyperphosphatemia and hyper-parathyroidism in dialysis patients:Recommendations for a change in management. Am JKidney Dis 35:1226-1237, 2000

• 2) Block GA, Massen PS, Lazarus JM, et al:Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218, 2004

• 3) Goodman WG, Goldin J, Kuizon BD, et al:Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
  pubmed

• 4) Chertow GM, Burke SK, Raggi P (the Treat to Goal Working Group):Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kdney lnt 62:245-252, 2002

• 5) Chertow GM, Raggi P, Chasan-Taber S, et al:Determinants of progressive vascular calcificationin haemodialysis patients. Nephrol Dial Transplant 19:1489-1496, 2004

• 6) Plone MA, Petersen JS, Rosenbaum DP, et al:Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. Clin Pharmacokinet 41:517-523, 2002
  pubmed

• 7) 永野伸郎,福島 直:慢性腎不全患者の高リン血症に対する新規リン結合性ポリマー (塩酸セベラマー) の薬理作用ならびに臨床試験成績.日薬理誌 122:443-453, 2003
  Medical*Online

• 8) 永野伸郎,小花幸子,宮田そのえほか:新規リン吸着剤sevelamer hydrochlorideの血中コレステロール低下作用機序.透析会誌 36:47-54, 2003

• 9) Nagano N, Miyata S, Obana S, et al:Renal mineral handling in normal rats treated with sevelamer hydrochloride (RenagelR), a noncalcemic phosphate binder. Nephron 89:321-328, 2001

• 10) Nagano N, Miyata S, Obana S, et al:Sevelamer hydrochloride, a calcium-free phosphate binder, inhibits parathyroid cell proliferation in par-tially nephrectomized rats. Nephrol Dial Transplant 18 (Suppl 3):81-85, 2003

• 11) Nagano N, Miyata S, Onaba S, et al:Sevelamer hydrochloride (Renagel?), anon-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 16:1870-1878, 2001

• 12) Katsumata K, Kusano K, Hirata M, et al:Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 64:441-450, 2003
  pubmed

• 13) Nagano N, Miyata S, Obana S, et al:Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 18:2014-2023, 2003
  pubmed

• 14) 草野健一郎,勝俣京子,平田道則ほか:腎不全ラットの高リン血症に対する塩酸セベラマーの治療効果.薬理と治療 31:203-207, 2003
  Medical*Online

• 15) 永野伸郎,宮田そのえ,阿部めぐみほか:正常および腎不全ラットにおけるsevelamer hydro-chloride投与後の血清リンおよび副甲状腺ホルモン値の時間変化-時間制限給餌下での検討-.透析会誌 37:1423-1429, 2004

• 16) Silver J, Kilav R, Naveh-Many T:Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 283:F367-376, 2002
  pubmed

• 17) Jono S, McKee MD, Murry CE, et al:Phosphate regulation ofvasucular smooth muscle cell calcification. Cir Res 87:E10-E17, 2000

• 18) 三輪谷博史,内野盛恵,秋澤忠男ほか:リン結合剤PB-94 (Sevelamer Hydrochloride) の臨床第 I相試験-単回投与試験-.臨床医薬 19:547-555, 2003
  Medical*Online

• 19) 三輪谷博史,秋澤忠男:リン結合剤PB-94 (Sevelamer Hydrochloride) の臨床第I相試験-反復投与試験-.臨床医薬 19:557-567, 2003
  Medical*Online

• 20) 栗原 怜,鈴木正司,二瓶 宏ほか:透析患者の高リン血症に対するリン結合剤PB-94 (Sevelamer Hydrochloride) の効果-第II相用量設定試験-.腎と透析55:221-238, 2003

• 21) 鈴木正司,栗原 怜,大薗英一ほか:血液透析患者の高リン血症に対するリン結合剤PB-94 (Sevelamer Hydrochloride) の効果-沈降炭酸カルシウム製剤 (カルタン(R)錠500) を対照とした比較臨床試験-.腎と透析55:383-400, 2003

• 22) 大森浩之,鈴木正司,栗原 怜ほか:血液透析患者の高リン血症に対するリン結合剤PB-94 (Sevelamer Hydrochloride) の効果-長期投与試験-.腎と透析 55:513-531, 2003

• 23) 平松 信,東海林隆男,新倉一彦ほか:腹膜透析患者の高リン血症に対するリン結合剤PB-94 (Sevelamer Hydrochloride) の効果-第III相一般臨床試験-.腎と透析 55:653-663, 2003

• 24) Collins AJ, St Peter WL, Dalleska FW, et al:Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol 54:334-341, 2000
  pubmed

• 25) Qunibi WY, Hootkins RE, McDowell LL, et al:Treatment of hyperphosphatemia in hemodialysis patients:The Calcium Acetate Renagel Evaluation (CARE Study). Kid Int 65:1914-1926, 2004

• 26) De Smet R, Thermote F, Lameire N, et al:Sevelamer hydrochloride (Renagel ?) adsorbs the uremic compound indoxyl sulfate. ERA-EDTA XLI Congress Abstract Book, p104-105, 2004

• 27) Burke SK, Amin N, Incerti C, et al:Sevelamer hydrochloride (Renagel?), anonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. J Clin Pharmacol 41:193-198, 2001

• 28) Burke SK, Amin NS, Incerti C, et al:Sevelamer hydrochloride (Renagel?), aphosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers. J Clin Pharmacol 41:199-205, 2001

• 29) Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, et al:Effect of phosphate binders on supplemental iron absorption in healthy subjects. J Clin Pharmacol 42:1171-1176, 2002
  pubmed

P.358 掲載の参考文献

• 1) 川口良人,高久史麿,前田貞亮ほか:腎性貧血患者に対するRecombinant Human Erythropoietin (KRN5702) の長期投与による臨床的有用性の検討.臨床医薬 4:2075. 2100, 1988

• 2) Clyne N, Jogestrand T:Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 60:390-396, 1992
  pubmed

• 3) Bedani PL, Verzola A, Bergami M, et al:Erythropoietin and cardiocirculatory condition in aged patients with chronic renal failure. Nephron 89:350-353, 2001
  pubmed

• 4) Wu SC, Lin SL, Jeng FR:Influence of erythro-poietin treatment on gonadotropic hormone levels and sexual function in male uremic patients, Scand J Urol Nephrol 35:136-140, 2001

• 5) Revicki DA, Brown RE, Feeny DH, et al:Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25:548-554, 1995
  pubmed

• 6) Furuland H, Linde T, Ahlmen J, et al:Arandomized controlled trial ofhaemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18:353-361, 2003

• 7) Xia H, Ebben J, Ma JZ, et al:Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10:1309-1316, 1999
  pubmed

• 8) Egrie JC, Browne JK:Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84 (suppl 1):3-10, 2001

• 9) Macdougall IC:Novel erythropoiesis stimulating protein. Semin Nephrol 20:375-381, 2000
  pubmed

• 10) Egrie JC, Dwyer E, Browne JK, et al:Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290-299, 2003

• 11) Akahori H, Tawara T, Ida M, et al:The effect of novel erythropoiesis stimulating Protein (NESP) on anemia induced by renal failure in rats. Exp Hematol 26:766, 1998

• 12) Macdougall IC, Gray SJ, Elston O, et al:Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10:2392-2395, 1999
  pubmed

• 13) Macdougall IC, Matcham J, Gray SJ:Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant 18:576-581, 2003
  pubmed

• 14) Vanrenterghem Y, Barany P, Mann JFE, et al:Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 62:2167-2175, 2002

• 15) Casadevall N, Nataf J, Viron B, et al:Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475, 2002
  pubmed

• 16) http://wwwext.amgen.com/clinicians/prca./html

P.362 掲載の参考文献

• 1) Nemeth EF:Pharmacological regulation of parathyroid hormone secretion. Curr Pharm Des 8:2077-2087, 2002
  pubmed

• 2) Nemeth EF, Heaton WH, Miller M, et al:Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCI. J Pharmacol Exp Ther 308:627-635, 2004

• 3) Wada M, Nagano N, Nemeth EF:The calcium receptor and calcimimetics. Curr Opin Nephrol Hypertens 8:429-433, 1999
  pubmed

• 4) Wada M, Furuya Y, Kobayashi N:The calcimimetic compound AMG073 (cinacalcet HCI) ameliorates osteitis fibrosa in rats with chronic renal insufficiency. J Am Soc Nephrol 14:48A, 2003

• 5) Wada M, Kawata T, Furuya Y:The calcimimetic compound KRN1493 suppresses parathyroid hyperplasia in rats with chronic renal in-sufficiency. J Bone Miner Res 17 (suppl 1):S212, 2002

• 6) Wada M, Furuya Y, Sakiyama JI, et al:The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency:Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100:2977-2983, 1997

• 7) Block GA, Martin KJ, Francisco ALM, et al:Cinacalcet for secondary hyperparathyroidism in patients receiving Hemodialysis. New Engl JMed 350:1516-1525, 2004

• 8) Torres PU:Clinical experience with cinacalcet HCl. Nephrol Dial Transplant 19 (suppl 5):v27-33, 2004

• 9) Cunningham J, Chertow G, Goodman W, et al:The effect of cinacalcet HCl on parathyroidectomy, fracture, hospitalization, and mortality in dialysis subjects with secondary hyperpar-athyroidism (HPT). XLI Congress Abstract Book, Eur Dialysis Transplant Assoc, p219, 2004

• 10) Ohashi N, Uematsu T, Nagashima S, et al:The calcimimetic agent KRN 149310wers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day ofhaemodialysis and on the day without haemodialysis. Br J Clin Pharmacol 57:726-734, 2004

• 11) National Kidney Foundation:K/DOQI Clinical practice guideline for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3):S1-202, 2003

• 12) Block GA, Klassen PS, Lazarus JM, et al:Mineral metabolism, mortality, and morbidity in maintenance Hemodialysis. J Am Soc Nephrol 15:2208-2218, 2004
  pubmed